{"id":19869,"date":"2024-06-18T04:15:00","date_gmt":"2024-06-17T20:15:00","guid":{"rendered":"https:\/\/www.franchise.com.hk\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869"},"modified":"2024-06-18T04:15:00","modified_gmt":"2024-06-17T20:15:00","slug":"%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all","status":"publish","type":"post","link":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869","title":{"rendered":"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277"},"content":{"rendered":"<p><span class=\"legendSpanClass\">\u4e2d\u570b\u8607\u5dde\u548c\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e<\/span><span class=\"legendSpanClass\">2024\u5e746\u670818\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff1b\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u7684\u4e09\u9805\u7814\u7a76\u6700\u65b0\u6578\u64da\uff0c\u5df2\u57282024\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703\uff08EHA 2024\uff09\u4e0a\u4ee5\u58c1\u5831\u5f62\u5f0f\u516c\u4f48\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>\u5176\u4e2d\uff0c\u57282023\u5e74\u7f8e\u570b\u8840\u6db2\u5b78\u6703\u5e74\u6703\u516c\u4f48\u7684\u6578\u64da\u57fa\u790e\u4e0a\uff0c\u516c\u53f8\u66f4\u65b0\u4e86\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7814\u7a76\u7684\u4e2d\u4f4d1\u5e74\u96a8\u8a2a\u6578\u64da\u3002\u7d50\u679c\u986f\u793a\u5c0d\u65bc\u7d93\u904e\u591a\u500bTKI\u6cbb\u7642\uff08\u5305\u62ec\u5c0dponatinib\u6216\/\u548casciminib\u8010\u85e5\uff09\uff0c\u4f34\u6709\u6216\u4e0d\u4f34\u6709T315I\u7a81\u8b8a\uff0c\u8010\u7acb\u514b\u00ae\u90fd\u8868\u73fe\u51fa\u512a\u7570\u6301\u7e8c\u7684\u81e8\u5e8a\u7642\u6548\uff0c\u60a3\u8005\u9577\u671f\u85e5\u7269\u8010\u53d7\u6027\u826f\u597d\u3002<\/p>\n<p>\u8a72\u9805\u81e8\u5e8a\u7814\u7a76\u7684\u4e3b\u8981\u7814\u7a76\u8005\u3001MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u767d\u8840\u75c5\u79d1\u7684<span class=\"xn-person\">Elia Jabbour<\/span>\u535a\u58eb\u8868\u793a\uff1a\u300c\u7814\u7a76\u8868\u660e\uff0c\u8010\u7acb\u514b\u00ae\u5728\u91dd\u5c0d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684CML\u548cPh+ ALL\uff08\u5305\u62ec\u5c0dponatinib\u548casciminib\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff09\u7684\u60a3\u8005\u6642\uff0c\u5177\u6709\u986f\u8457\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002\u9019\u610f\u5473\u8457\u8010\u7acb\u514b\u00ae\u6709\u6f5b\u529b\u70ba\u9019\u4e00\u5177\u6709\u6311\u6230\u6027\u7684\u60a3\u8005\u7fa4\u9ad4\u63d0\u4f9b\u6709\u50f9\u503c\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u9700\u8981\u901a\u904e\u9577\u671f\u7814\u7a76\u9032\u4e00\u6b65\u9a57\u8b49\u5176\u81e8\u5e8a\u512a\u52e2\u3002\u300d<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4ee5\u5f80\u9032\u5c55\u548c\u672c\u6b21\u5728EHA\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u6700\u65b0\u6578\u64da\uff0c\u518d\u6b21\u8b49\u660e\u4e86\u8010\u7acb\u514b\u00ae\u5728ponatinib\u548casciminib\u8010\u85e5\u60a3\u8005\u4e2d\u7684\u5de8\u5927\u6f5b\u529b\u3002\u6211\u5011\u5c07\u52a0\u5feb\u9019\u4e00\u5168\u7403\u300eBest-in-class\u300f\u7522\u54c1\u7684\u81e8\u5e8a\u958b\u767c\uff0c\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d<\/p>\n<p>\u8010\u7acb\u514b\u00ae\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u5168\u7403\u5c64\u9762\u300cBest-in-class\u300d\u85e5\u7269\u3002\u4f5c\u70ba\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u8a72\u7522\u54c1\u76ee\u524d\u5df2\u6709\u5169\u9805\u9069\u61c9\u75c7\u7372\u6279\uff0c\u5206\u5225\u70ba\u6cbb\u7642\u4efb\u4f55TKI\u8010\u85e5\u3001\u4e26\u4f34\u6709T315I\u7a81\u8b8a\u7684CML\u6162\u6027\u671f\uff08-CP\uff09\u548c\u52a0\u901f\u671f\uff08-AP\uff09\u7684\u6210\u5e74\u60a3\u8005\uff1b\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8010\u7acb\u514b\u00ae\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u6709\u4e00\u9805\u6cbb\u7642\u521d\u6cbbPh+ ALL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\uff0c\u610f\u5473\u8457\u5176\u6709\u671b\u6210\u70ba\u570b\u5167\u9996\u500b\u7372\u6279\u7684\u7528\u65bcPh+ ALL\u4e00\u7dda\u6cbb\u7642\u7684TKI\u3002<\/p>\n<p>EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002\u4e9e\u76db\u91ab\u85e5\u9084\u5728\u672c\u5c46\u5927\u6703\u4e0a\u516c\u4f48\u4e86Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7684\u6700\u65b0\u7814\u7a76\u9032\u5c55\u3002<\/p>\n<p>\u8010\u7acb\u514b\u00ae\u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff1a<\/p>\n<p>Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)<\/p>\n<p>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u5c0dPonatinib\u548cAsciminib\u7684\u8010\u85e5<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1aP722   \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a   \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical)   \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593)   \u5831\u544a\u4eba\uff1aElias Jabbour\u535a\u58eb\uff0c\u5fb7\u5dde\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3  <\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u4e00\u6b3e\u65b0\u578b\u5f37\u6548BCR::ABL1 TKI\uff0c\u76ee\u524d\u5df2\u6709\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u6578\u64da\u8b49\u5be6\u5176\u5728CML\u6216Ph+ ALL\u7684\u60a3\u8005\u4e2d\u5177\u6709\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\u3002<br \/>\n\u7814\u7a76\u4ecb\u7d39\uff1a\u9019\u662f\u4e00\u9805\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecPonatinib\u548cAsciminib\uff09\u7684CML\u6216Ph+ ALL\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002<br \/>\n\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a\u622a\u81f32024\u5e741\u67082\u65e5\uff0c\u672c\u7814\u7a76\u5171\u7d0d\u516580\u4f8b\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\u60a3\u8005\uff0c\u5305\u62ec62\u4f8bCML-CP\u548c18\u4f8b\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\uff08\u5305\u62ecCML-AP, CML-BP, \u548cPh+ ALL\uff09\u60a3\u8005\u3002\u60a3\u8005\u96a8\u6a5f\u5206\u914d\u81f330mg\u300140mg\u548c50 mg\u5291\u91cf\u7d44\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u63a1\u7528\u9694\u5929\u4e00\u6b21\uff08QOD\uff09\u53e3\u670d\u7d66\u85e5\u65b9\u6848\uff0c\u6bcf28\u5929\u70ba\u4e00\u500b\u7d66\u85e5\u9031\u671f\u3002<br \/>\n\u7642\u6548\u6578\u64da\uff1a<br \/>\n1)\u00a0 CML-CP\u60a3\u8005\uff1a<br \/>\n31\/51\uff0860.8%\uff09\u60a3\u8005\u7372\u5f97\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\uff0c25\/59\uff0842.4%\uff09\u60a3\u8005\u7372\u5f97\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u3002\u4e14\u53cd\u61c9\u7387\u8207\u662f\u5426\u4f34\u6709T315I\u7a81\u8b8a\u7121\u5dee\u7570\uff1b\u00a0       \u65e2\u5f80ponatinib\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u4e2d\uff0c\u517115\/26\uff0857.7%\uff09\u7372\u5f97CCyR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e5\u60a3\u800510\/19 [52.6%]\u4f8b\u548c\u4e0d\u8010\u53d7\u60a3\u80053\/4[75.0%]\u4f8b\uff09\uff1b\u517111\/30\uff0836.7%\uff09\u7372\u5f97MMR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e59\/21[42.9%]\u548c\u4e0d\u8010\u53d71\/6[16.7%]\uff09\uff1b\u00a0       \u65e2\u5f80Asciminib\u6cbb\u7642\u8010\u85e5\u7684\u60a3\u8005\u4e2d\uff0c4\/8\uff0850.0%\uff09\u7372\u5f97CCyR, 4\/12\uff0833.3%\uff09\u7372\u5f97MMR\u3002<br \/>\n     2)\u00a0 \u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\uff1a<br \/>\n3\/14\uff0821.4%\uff09\u60a3\u8005\u7372\u5f97CCyR\uff0c3\/17\uff0817.6%\uff09\u60a3\u8005\u7372\u5f97MMR\u3002      <\/p>\n<p>\u5b89\u5168\u6027\u6578\u64da\uff1a<br \/>\n72\u4f8b\uff0890.0%\uff09\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u7d93\u6b77\u4e86\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u5176\u4e2d\u5927\u90e8\u5206\u70ba\u8f15\u5ea6\u6216\u4e2d\u5ea6\uff1b     \u8f03\u5e38\u898b\u7684\u22653\u7d1aTEAEs\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0817.5%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0812.5%\uff09\u548c\u8840\u808c\u9178\u78f7\u9178\u6fc0\u9176\u5347\u9ad8\uff0812.5%\uff09\uff1b\u767c\u751f\u5728\u22653\u4f8b\uff083.8%\uff09\u60a3\u8005\u4e2d\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\u5305\u62ec\u623f\u986b\u3001COVID-19\u611f\u67d3\u3001\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u548c\u8178\u6897\u963b\uff1b\u7121\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAE\uff09\u5c0e\u81f4\u60a3\u8005\u6b7b\u4ea1\u3002\u5169\u4f8b\uff082.5%\uff09\u60a3\u8005\u767c\u751f1\u7d1a\u8207\u6cbb\u7642\u76f8\u95dc\u7684\u52d5\u8108\u8840\u7ba1\u9589\u585e\u4e8b\u4ef6\uff0c\u5206\u5225\u70ba\u5fc3\u7d5e\u75db\u548c\u5fc3\u529b\u8870\u7aed\u3002    <\/p>\n<p>\u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecponatinib\u6216asciminib\u8010\u85e5\/\u4e0d\u8010\u53d7\uff09\u7684CML-CP\u548c\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u6297\u816b\u7624\u4f5c\u7528\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002  <\/p>\n<p>Combination\u00a0of Third Generation\u00a0TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+\u00a0ALL Patients<\/p>\n<p>\u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216Blinatumomab\u7528\u65bc\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+ ALL\u6210\u4eba\u60a3\u8005<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1aP427   \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a   \u5206\u6703\u5834\u6a19\u984c\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76(Acute lymphoblastic leukemia \u2013 Clinical)   \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593)   \u5831\u544a\u4eba\uff1a\u9673\u4fca\u5091\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662  <\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1aTKI\u6539\u5584\u4e86Ph+ ALL\u60a3\u8005\u7684\u9577\u671f\u9810\u5f8c\uff0c\u4f46TKI\u8010\u85e5\u554f\u984c\u4ecd\u7136\u662f\u4e00\u500b\u6311\u6230\u3002\u65e2\u5f80\u5831\u544a\u986f\u793a\uff0c\u7b2c\u4e09\u4ee3TKI Ponatinib\u806f\u5408\u5316\u7642\u5728\u4e09\u500b\u6708\u5167\u7684\u5b8c\u5168\u5206\u5b50\u5b78\u7de9\u89e3\u7387\uff08CMR\uff09\u53ef\u905475%\u3002\u5728\u6700\u8fd1\u7684\u4e00\u9805\u7814\u7a76\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408PDT-ALL-2016\u65b9\u6848\u4e00\u7dda\u6cbb\u7642Ph+ ALL\u986f\u793a\u51fa\u4e86\u826f\u597d\u7684\u7d50\u679c\uff0c\u6cbb\u7642\u5f8c\u7b2c90\u5929\u7684CMR\u7387\u70ba84.6%\u3002\u6b64\u5916\uff0cTKI\u806f\u5408blinatumomab\uff08BITE\uff09\u7684\u7121\u5316\u7642\u65b9\u6848\u5df2\u986f\u793a\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002<br \/>\n\u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\uff08TKI+\u5316\u7642\uff09\u53ca\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408blinatumomab\uff08TKI+BITE\uff09\u7528\u65bc\u4e00\u7dda\u6cbb\u7642 Ph+ ALL \u7684\u81e8\u5e8a\u7642\u6548\u3002<br \/>\n\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a2022\u5e741\u6708\u81f32023\u5e7412\u6708\uff0c\u7814\u7a76\u5165\u7d44\u4e8631\u4f8b\u65b0\u78ba\u8a3a\u7684Ph+ ALL\u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\uff0840mg\uff0c\u9694\u65e5\u4e00\u6b21\uff09\u806f\u5408\u5152\u7ae5\u555f\u767c\u5316\u7642\uff08n=19\uff1bPDT-ALL-2016\u65b9\u6848\uff09\u6216blinatumomab\uff08n=12\uff1b\u7d66\u85e52\u5468\uff0c 2\u5468\u7121\u6cbb\u7642\u9593\u6b47\u671f\uff09\u7684\u6cbb\u7642\u3002\u60a3\u8005\u4e2d\u4f4d\u5e74\u9f61\u70ba40\u6b72\uff0c15\u4f8b\uff0848.4%\uff09\u60a3\u8005\u5408\u4f751\u7a2e\u5408\u4f75\u75c7\uff0c8\u4f8b\uff0825.81%\uff09\u60a3\u8005\u67092\u7a2e\u4ee5\u4e0a\u5408\u4f75\u75c7\u3002<br \/>\n\u7642\u6548\u6578\u64da\uff1a\u4e2d\u4f4d\u96a8\u8a2a16\u500b\u6708\u5f8c\uff0c\u6240\u6709\u60a3\u8005\u5728\u63a5\u53d71\u500b\u6cbb\u7642\u9031\u671f\u5f8c\u5747\u7372\u5f97\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u3002\u7e3d\u968a\u5217\u4e2d\uff0c28\u4f8b\uff0890.3%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u5176\u4e2d\uff0cTKI+\u5316\u7642\u968a\u5217\u548cTKI+BITE\u968a\u5217\u5206\u5225\u670916\u4f8b\uff0884.2%\uff09\u548c12\u4f8b\uff08100.0%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u7e3d\u968a\u5217\u76841\u5e74\u7e3d\u751f\u5b58\uff08OS\uff09\u7387\u70ba93.1%\uff0c\u7121\u4e8b\u4ef6\u751f\u5b58\uff08EFS\uff09\u7387\u70ba78.4%\u3002TKI+\u5316\u7642\u968a\u5217\u76841\u5e74OS\u7387\u70ba96.2%\uff0cEFS\u7387\u70ba71.5%\u3002TKI+BITE\u968a\u5217\u76841\u5e74OS\u7387\u70ba 100.0%\uff0cEFS\u7387\u70ba90.0%\u3002<br \/>\n\u5b89\u5168\u6027\u6578\u64da\uff1a\u572810\u4f8b\uff0832.3%\uff09\u60a3\u8005\u4e2d\u89c0\u5bdf\u5230\u4e0d\u826f\u4e8b\u4ef6\uff0c3\u4f8b\uff089.6%\uff09\u60a3\u8005\u5728\u6cbb\u7642\u671f\u9593\u767c\u751f\u611f\u67d3\u6027\u4f11\u514b\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u51fa\u73fe\u8f15\u5ea6\u80f0\u817a\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f\u8036\u6c0f\u80ba\u5b62\u5b50\u83cc\u80ba\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f2\u7d1a\u7d30\u80de\u56e0\u5b50\u91cb\u653e\u7d9c\u5408\u5f81\uff08CRS\uff09\uff1b1\u4f8b\uff083.2%\uff09\u60a3\u8005\u767c\u751f\u80ba\u6813\u585e\u3002<br \/>\n\u7d50\u8ad6\uff1a\u9019\u9805\u7814\u7a76\u5c0d\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216blinatumomab\u6cbb\u7642\u6210\u4ebaPh+ ALL\u60a3\u8005\u9032\u884c\u4e86\u8a55\u4f30\u3002\u5728\u5165\u7d44\u768431\u4f8b\u60a3\u8005\u4e2d\uff0c\u89c0\u5bdf\u5230\u4e86\u986f\u8457\u76841\u5e74\u751f\u5b58\u7387\u548cCMR \u7387\uff0c\u9019\u70ba\u63d0\u9ad8\u9577\u671f\u751f\u5b58\u7387\u5e36\u4f86\u4e86\u5e0c\u671b\u3002TKI+\u5316\u7642\u548cTKI+BITE\u968a\u5217\u90fd\u986f\u793a\u4e86\u826f\u597d\u7684\u81e8\u5e8a\u7d50\u679c\uff0c\u4e14TKI+BITE\u968a\u5217\u7684\u751f\u5b58\u6f5b\u529b\u512a\u65bcTKI+\u5316\u7642\u968a\u5217\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u5118\u7ba174.19%\u7684\u60a3\u8005\u6709\u81f3\u5c11\u4e00\u7a2e\u5408\u4f75\u75c7\uff0c\u4e2d\u4f4d\u5e74\u9f61\u905440\u6b72\uff0c\u5b89\u5168\u6027\u4ecd\u53ef\u63a5\u53d7\u3002  <\/p>\n<p>Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy<\/p>\n<p>\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u6210\u5e74\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1aP1862   \u5c55\u793a\u985e\u578b\uff1a\u96fb\u5b50\u58c1\u5831\u5c55\u793a   \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical)   \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593)   \u5831\u544a\u4eba\uff1a\u65bc\u9732\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662  <\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1a\u7b2c\u4e09\u4ee3TKI\u6539\u5584\u4e86TKI\u8010\u85e5\u7684CML\u60a3\u8005\u7684\u9810\u5f8c\u3002\u7136\u800c\uff0c\u95dc\u65bc\u63a5\u53d7\u5982\u5967\u96f7\u5df4\u66ff\u5c3c\u7b49\u7b2c\u4e09\u4ee3TKI\u7684\u6210\u5e74\u60a3\u8005\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40\u6578\u64da\u5f88\u5c11\u3002<br \/>\n\u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5CML\u60a3\u8005\u7684\u5065\u5eb7\u76f8\u95dc\u751f\u6d3b\u8cea\u91cf\uff08HRQoL\uff09\u3001\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\uff0c\u4e26\u78ba\u5b9a\u8207\u4e4b\u76f8\u95dc\u7684\u8b8a\u91cf\u3002<br \/>\n\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<br \/>\n\u8a72\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\u4e2d\uff0c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u7684\u60a3\u8005\u5728\u57fa\u7dda\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u5b9a\u671f\u5b8c\u6210\u6b50\u6d32\u764c\u75c7\u7814\u7a76\u8207\u6cbb\u7642\u7d44\u7e54\uff08EORTC\uff09\u751f\u547d\u8cea\u91cf\u8a55\u4f30\u554f\u5377\uff08QLQ-C30\uff09\u3001\u7126\u616e\u81ea\u8a55\u91cf\u8868\uff08SAS\uff09\u548c\u6291\u9b31\u81ea\u8a55\u91cf\u8868\uff08SDS\uff09\u3002\u7814\u7a76\u901a\u904e\u57fa\u65bc\u7368\u7acb\u5de5\u4f5c\u76f8\u95dc\u77e9\u9663\u7684\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u7dda\u6027\u6a21\u578b\uff0c\u4f30\u8a08\u60a3\u8005\u5831\u544a\u7d50\u5c40\u96a8\u6642\u9593\u8b8a\u5316\u8da8\u52e2\uff0c\u4e26\u4f7f\u7528\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u6a21\u578b\u8a55\u4f30\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u548c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684\u6cbb\u7642\u53cd\u61c9\u5c0dHRQoL\u3001SAS\u548cSDS\u7684\u5f71\u97ff\u3002     \u672c\u7814\u7a76\u5171\u7d0d\u5165159\u4f8b\u8655\u65bcCP\u6216AP\u7684CML\u60a3\u8005\u3002\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f61\u70ba 42\uff0820-74\uff09\u6b72\u3002104\u4f8b\uff0865%\uff09\u60a3\u8005\u70ba\u7537\u6027\u3002\u5f9e\u78ba\u8a3aCML\u5230\u958b\u59cb\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u6642\u9593\u9593\u9694\u70ba5\uff080.3-23\uff09\u5e74\u300277\u4f8b\uff0848%\uff09\u60a3\u8005\u5728\u78ba\u8a3aCML\u5f8c\u76845\u5e74\u5167\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u3002\u6240\u6709\u60a3\u8005\u90fd\u5b8c\u6210\u4e86QLQ-C30\u554f\u5377\uff0c115\u4f8b\u60a3\u8005\u5b8c\u6210\u4e86SAS\u548cSDS\u554f\u5377\u3002    <\/p>\n<p>\u554f\u5377\u6578\u64da\uff1a<br \/>\n\u6839\u64daEORTC QLQ-C30\u554f\u5377\u8a55\u4f30\uff0c\u57fa\u7dda\u6642\u6700\u56b4\u91cd\u76843\u7a2e\u75c7\u72c0\u8ca0\u64d4\u70ba\u7d93\u6fdf\u56f0\u96e3\u3001\u75b2\u52de\u548c\u5931\u7720\u3002\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\uff0c\u5305\u62ec\u6574\u9ad4\u5065\u5eb7\u3001\u8eab\u9ad4\u529f\u80fd\u3001\u60c5\u611f\u529f\u80fd\u3001\u75b2\u52de\u3001\u75bc\u75db\u3001\u547c\u5438\u56f0\u96e3\u3001\u8179\u7009\u548c\u7d93\u6fdf\u56f0\u96e3\u5728\u5167\u76848\u500b\u91cf\u8868\u9805\u76ee\u7372\u5f97\u986f\u8457\u6539\u5584\u3002\u6c92\u6709\u91cf\u8868\u9805\u76ee\u51fa\u73fe\u986f\u8457\u60e1\u5316\u3002\u5728\u591a\u8b8a\u91cf\u5206\u6790\u4e2d\uff0c\u5e74\u9f61&lt;40\u6b72\u8207\u66f4\u597d\u7684\u793e\u6703\u529f\u80fd\u6539\u5584\u76f8\u95dc\uff08p=0.021\uff09\uff1bCP\u60a3\u8005\uff08\u8207AP\u76f8\u6bd4\uff09\u547c\u5438\u56f0\u96e3\uff08p=0.028\uff09\u548c\u8179\u7009\uff08p=0.042\uff09\u5f97\u5230\u66f4\u597d\u7684\u6539\u5584\uff1b\u9054\u5230MMR\u5f8c\uff0c\u6574\u9ad4\u5065\u5eb7\uff08p=0.005\uff09\u3001\u5641\u5fc3\u5614\u5410\uff08p=0.009\uff09\u548c\u8179\u7009\uff08p=0.001\uff09\u90fd\u7372\u5f97\u66f4\u597d\u7684\u6539\u5584\u3002     \u57fa\u7dda\u6642\uff0c\u6839\u64daSAS\u8a55\u5206\uff0c\u670996\u4f8b\uff0884%\uff09\u60a3\u8005\u6b63\u5e38\uff0c19\u4f8b\uff0816%\uff09\u60a3\u8005\u6709\u8f15\u5ea6\u6216\u4e2d\u5ea6\u7126\u616e\u75c7\u72c0\u3002\u6839\u64daSDS\u8a55\u5206\uff0c64\u4f8b\uff0856%\uff09\u60a3\u8005\u6b63\u5e38\uff1b37\u4f8b\uff0832%\uff09\u6709\u8f15\u5ea6\u6291\u9b31\u75c7\u72c0\uff0c14\u4f8b\uff0812%\uff09\u6709\u4e2d\u5ea6\u6216\u91cd\u5ea6\u6291\u9b31\u75c7\u72c0\u3002SAS\u8a55\u5206\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u96a8\u6642\u9593\u63a8\u9032\u986f\u8457\u964d\u4f4e\uff08p&lt;0.001\uff09\uff0c\u800cSDS\u8a55\u5206\u6c92\u6709\u986f\u8457\u8b8a\u5316\u3002\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642 \u7684\u7b2c36\u500b\u6708\uff0c\u5206\u5225\u670978\u4f8b\uff0895%\uff09\u548c48\u4f8b\uff0859%\uff09\u60a3\u8005\u6839\u64daSAS\u548cSDS\u554f\u5377\u8a55\u4f30\u7d50\u679c\u88ab\u8a8d\u5b9a\u70ba\u6c92\u6709\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\u3002\u6c92\u6709\u767c\u73fe\u4efb\u4f55\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u5f71\u97ffSAS\u8a55\u5206\u8b8a\u5316\u7684\u8b8a\u91cf\u3002    <\/p>\n<p>\u7d50\u8ad6\uff1aTKI\u8010\u85e5CML\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684HRQoL\u548c\u7126\u616e\u75c7\u72c0\u96a8\u6642\u9593\u7684\u5ef6\u9577\u6709\u986f\u8457\u6539\u5584\u3002\u5e74\u9f61\u8f03\u5c0f\uff0c\u8655\u65bcCP\u671f\uff0c\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u9054\u5230MMR\u7684\u60a3\u8005\u7684HRQoL\u6539\u5584\u60c5\u6cc1\u66f4\u597d\u3002  <\/p>\n<p>\u95dc\u65bc\u4e9e\u76db\u91ab\u85e5<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u570b\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u7684\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9e\u76db\u91ab\u85e5\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u64c1\u6709\u81ea\u4e3b\u69cb\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u85e5\u7269\u8a2d\u8a08\u5e73\u53f0\uff0c\u8655\u65bc\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u85e5\u7814\u767c\u7684\u5168\u7403\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u64c1\u67099\u500b\u5df2\u9032\u5165\u81e8\u5e8a\u958b\u767c\u968e\u6bb5\u76841\u985e\u5c0f\u5206\u5b50\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP\u6216MDM2-p53\u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\uff0c\u70ba\u5168\u7403\u552f\u4e00\u5728\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u9818\u57df\u5747\u6709\u81e8\u5e8a\u958b\u767c\u54c1\u7a2e\u7684\u5275\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u570b\u3001\u7f8e\u570b\u3001\u6fb3\u5927\u5229\u4e9e\u53ca\u6b50\u6d32\u958b\u5c5540\u591a\u9805\u81e8\u5e8a\u8a66\u9a57\uff0c\u5176\u4e2d5\u9805\u70ba\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u3002<\/p>\n<p>\u7528\u65bc\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u7a2e\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u66fe\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u65b0\u85e5\u5be9\u8a55\u4e2d\u5fc3\uff08CDE\uff09\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u548c\u7a81\u7834\u6027\u6cbb\u7642\u54c1\u7a2e\uff0c\u4e26\u5df2\u5728\u4e2d\u570b\u7372\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u500b\u4e0a\u5e02\u54c1\u7a2e\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u5df2\u88ab\u6210\u529f\u7d0d\u5165\u300a\u570b\u5bb6\u57fa\u672c\u91ab\u7642\u4fdd\u96aa\u3001\u5de5\u50b7\u4fdd\u96aa\u548c\u751f\u80b2\u4fdd\u96aa\u85e5\u54c1\u76ee\u9304(2022\u5e74)\u300b\u3002\u8a72\u54c1\u7a2e\u9084\u7372\u5f97\u4e86\u7f8e\u570bFDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u3001\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3001\u4ee5\u53ca\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3002<\/p>\n<p>\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u500b\u5728\u7814\u65b0\u85e5\u7372\u5f9716\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u516c\u53f8\u5148\u5f8c\u627f\u64d4\u591a\u9805\u570b\u5bb6\u79d1\u6280\u91cd\u5927\u5c08\u9805\uff0c\u5176\u4e2d\u300c\u91cd\u5927\u65b0\u85e5\u5275\u88fd\u300d\u5c08\u98055\u9805\uff0c\u5305\u62ec1\u9805\u300c\u4f01\u696d\u5275\u65b0\u85e5\u7269\u5b75\u5316\u57fa\u5730\u300d\u53ca4\u9805\u300c\u5275\u65b0\u85e5\u7269\u7814\u767c\u300d\uff0c\u53e6\u5916\u627f\u64d4\u300c\u91cd\u5927\u50b3\u67d3\u75c5\u9632\u6cbb\u300d\u5c08\u98051\u9805\u3002<\/p>\n<p>\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207UNITY\u3001MD Anderson\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u7b49\u9818\u5148\u7684\u751f\u7269\u6280\u8853\u53ca\u91ab\u85e5\u516c\u53f8\u3001\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u8c50\u5bcc\u7684\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u7d93\u9a57\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u540c\u6642\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6a19\u6e96\u6253\u9020\u5f8c\u671f\u7684\u5546\u696d\u5316\u751f\u7522\u53ca\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p>\u524d\u77bb\u6027\u8072\u660e<\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u8207\u672c\u6587\u4f5c\u51fa\u8a72\u9673\u8ff0\u7576\u65e5\u7684\u4e8b\u4ef6\u6216\u8cc7\u6599\u6709\u95dc\u3002\u9664\u6cd5\u5f8b\u898f\u5b9a\u5916\uff0c\u65bc\u4f5c\u51fa\u524d\u77bb\u6027\u9673\u8ff0\u7576\u65e5\u4e4b\u5f8c\uff0c\u7121\u8ad6\u662f\u5426\u51fa\u73fe\u65b0\u8cc7\u6599\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u6211\u5011\u4e26\u7121\u8cac\u4efb\u66f4\u65b0\u6216\u516c\u958b\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u9810\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8acb\u7d30\u95b1\u672c\u6587\uff0c\u4e26\u7406\u89e3\u6211\u5011\u7684\u5be6\u969b\u672a\u4f86\u696d\u7e3e\u6216\u8868\u73fe\u53ef\u80fd\u8207\u9810\u671f\u6709\u91cd\u5927\u5dee\u7570\u3002\u672c\u6587\u5167\u6240\u6709\u9673\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u767c\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u4f86\u767c\u5c55\u800c\u51fa\u73fe\u8b8a\u52d5\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u570b\u8607\u5dde\u548c\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e2024\u5e746\u670818\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff1b\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u7684\u4e09\u9805\u7814\u7a76\u6700\u65b0\u6578\u64da\uff0c\u5df2\u57282024\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703\uff08EHA 2024\uff09\u4e0a\u4ee5\u58c1\u5831\u5f62\u5f0f\u516c\u4f48\u3002 \u5176\u4e2d\uff0c\u57282023\u5e74\u7f8e\u570b\u8840\u6db2\u5b78\u6703\u5e74\u6703\u516c\u4f48\u7684\u6578\u64da\u57fa\u790e\u4e0a\uff0c\u516c\u53f8\u66f4\u65b0\u4e86\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7814\u7a76\u7684\u4e2d\u4f4d1\u5e74\u96a8\u8a2a\u6578\u64da\u3002\u7d50\u679c\u986f\u793a\u5c0d\u65bc\u7d93\u904e\u591a\u500bTKI\u6cbb\u7642\uff08\u5305\u62ec\u5c0dponatinib\u6216\/\u548casciminib\u8010\u85e5\uff09\uff0c\u4f34\u6709\u6216\u4e0d\u4f34\u6709T315I\u7a81\u8b8a\uff0c\u8010\u7acb\u514b\u00ae\u90fd\u8868\u73fe\u51fa\u512a\u7570\u6301\u7e8c\u7684\u81e8\u5e8a\u7642\u6548\uff0c\u60a3\u8005\u9577\u671f\u85e5\u7269\u8010\u53d7\u6027\u826f\u597d\u3002 \u8a72\u9805\u81e8\u5e8a\u7814\u7a76\u7684\u4e3b\u8981\u7814\u7a76\u8005\u3001MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u767d\u8840\u75c5\u79d1\u7684Elia Jabbour\u535a\u58eb\u8868\u793a\uff1a\u300c\u7814\u7a76\u8868\u660e\uff0c\u8010\u7acb\u514b\u00ae\u5728\u91dd\u5c0d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684CML\u548cPh+ ALL\uff08\u5305\u62ec\u5c0dponatinib\u548casciminib\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff09\u7684\u60a3\u8005\u6642\uff0c\u5177\u6709\u986f\u8457\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002\u9019\u610f\u5473\u8457\u8010\u7acb\u514b\u00ae\u6709\u6f5b\u529b\u70ba\u9019\u4e00\u5177\u6709\u6311\u6230\u6027\u7684\u60a3\u8005\u7fa4\u9ad4\u63d0\u4f9b\u6709\u50f9\u503c\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u9700\u8981\u901a\u904e\u9577\u671f\u7814\u7a76\u9032\u4e00\u6b65\u9a57\u8b49\u5176\u81e8\u5e8a\u512a\u52e2\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4ee5\u5f80\u9032\u5c55\u548c\u672c\u6b21\u5728EHA\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u6700\u65b0\u6578\u64da\uff0c\u518d\u6b21\u8b49\u660e\u4e86\u8010\u7acb\u514b\u00ae\u5728ponatinib\u548casciminib\u8010\u85e5\u60a3\u8005\u4e2d\u7684\u5de8\u5927\u6f5b\u529b\u3002\u6211\u5011\u5c07\u52a0\u5feb\u9019\u4e00\u5168\u7403\u300eBest-in-class\u300f\u7522\u54c1\u7684\u81e8\u5e8a\u958b\u767c\uff0c\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u8010\u7acb\u514b\u00ae\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u5168\u7403\u5c64\u9762\u300cBest-in-class\u300d\u85e5\u7269\u3002\u4f5c\u70ba\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u8a72\u7522\u54c1\u76ee\u524d\u5df2\u6709\u5169\u9805\u9069\u61c9\u75c7\u7372\u6279\uff0c\u5206\u5225\u70ba\u6cbb\u7642\u4efb\u4f55TKI\u8010\u85e5\u3001\u4e26\u4f34\u6709T315I\u7a81\u8b8a\u7684CML\u6162\u6027\u671f\uff08-CP\uff09\u548c\u52a0\u901f\u671f\uff08-AP\uff09\u7684\u6210\u5e74\u60a3\u8005\uff1b\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8010\u7acb\u514b\u00ae\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u6709\u4e00\u9805\u6cbb\u7642\u521d\u6cbbPh+ ALL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\uff0c\u610f\u5473\u8457\u5176\u6709\u671b\u6210\u70ba\u570b\u5167\u9996\u500b\u7372\u6279\u7684\u7528\u65bcPh+ ALL\u4e00\u7dda\u6cbb\u7642\u7684TKI\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002\u4e9e\u76db\u91ab\u85e5\u9084\u5728\u672c\u5c46\u5927\u6703\u4e0a\u516c\u4f48\u4e86Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7684\u6700\u65b0\u7814\u7a76\u9032\u5c55\u3002 \u8010\u7acb\u514b\u00ae\u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff1a Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u5c0dPonatinib\u548cAsciminib\u7684\u8010\u85e5 \u6458\u8981\u7de8\u865f\uff1aP722 \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1aElias Jabbour\u535a\u58eb\uff0c\u5fb7\u5dde\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u4e00\u6b3e\u65b0\u578b\u5f37\u6548BCR::ABL1 TKI\uff0c\u76ee\u524d\u5df2\u6709\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u6578\u64da\u8b49\u5be6\u5176\u5728CML\u6216Ph+ ALL\u7684\u60a3\u8005\u4e2d\u5177\u6709\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u9019\u662f\u4e00\u9805\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecPonatinib\u548cAsciminib\uff09\u7684CML\u6216Ph+ ALL\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a\u622a\u81f32024\u5e741\u67082\u65e5\uff0c\u672c\u7814\u7a76\u5171\u7d0d\u516580\u4f8b\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\u60a3\u8005\uff0c\u5305\u62ec62\u4f8bCML-CP\u548c18\u4f8b\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\uff08\u5305\u62ecCML-AP, CML-BP, \u548cPh+ ALL\uff09\u60a3\u8005\u3002\u60a3\u8005\u96a8\u6a5f\u5206\u914d\u81f330mg\u300140mg\u548c50 mg\u5291\u91cf\u7d44\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u63a1\u7528\u9694\u5929\u4e00\u6b21\uff08QOD\uff09\u53e3\u670d\u7d66\u85e5\u65b9\u6848\uff0c\u6bcf28\u5929\u70ba\u4e00\u500b\u7d66\u85e5\u9031\u671f\u3002 \u7642\u6548\u6578\u64da\uff1a 1)\u00a0 CML-CP\u60a3\u8005\uff1a 31\/51\uff0860.8%\uff09\u60a3\u8005\u7372\u5f97\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\uff0c25\/59\uff0842.4%\uff09\u60a3\u8005\u7372\u5f97\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u3002\u4e14\u53cd\u61c9\u7387\u8207\u662f\u5426\u4f34\u6709T315I\u7a81\u8b8a\u7121\u5dee\u7570\uff1b\u00a0 \u65e2\u5f80ponatinib\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u4e2d\uff0c\u517115\/26\uff0857.7%\uff09\u7372\u5f97CCyR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e5\u60a3\u800510\/19 [52.6%]\u4f8b\u548c\u4e0d\u8010\u53d7\u60a3\u80053\/4[75.0%]\u4f8b\uff09\uff1b\u517111\/30\uff0836.7%\uff09\u7372\u5f97MMR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e59\/21[42.9%]\u548c\u4e0d\u8010\u53d71\/6[16.7%]\uff09\uff1b\u00a0 \u65e2\u5f80Asciminib\u6cbb\u7642\u8010\u85e5\u7684\u60a3\u8005\u4e2d\uff0c4\/8\uff0850.0%\uff09\u7372\u5f97CCyR, 4\/12\uff0833.3%\uff09\u7372\u5f97MMR\u3002 2)\u00a0 \u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\uff1a 3\/14\uff0821.4%\uff09\u60a3\u8005\u7372\u5f97CCyR\uff0c3\/17\uff0817.6%\uff09\u60a3\u8005\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a 72\u4f8b\uff0890.0%\uff09\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u7d93\u6b77\u4e86\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u5176\u4e2d\u5927\u90e8\u5206\u70ba\u8f15\u5ea6\u6216\u4e2d\u5ea6\uff1b \u8f03\u5e38\u898b\u7684\u22653\u7d1aTEAEs\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0817.5%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0812.5%\uff09\u548c\u8840\u808c\u9178\u78f7\u9178\u6fc0\u9176\u5347\u9ad8\uff0812.5%\uff09\uff1b\u767c\u751f\u5728\u22653\u4f8b\uff083.8%\uff09\u60a3\u8005\u4e2d\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\u5305\u62ec\u623f\u986b\u3001COVID-19\u611f\u67d3\u3001\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u548c\u8178\u6897\u963b\uff1b\u7121\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAE\uff09\u5c0e\u81f4\u60a3\u8005\u6b7b\u4ea1\u3002\u5169\u4f8b\uff082.5%\uff09\u60a3\u8005\u767c\u751f1\u7d1a\u8207\u6cbb\u7642\u76f8\u95dc\u7684\u52d5\u8108\u8840\u7ba1\u9589\u585e\u4e8b\u4ef6\uff0c\u5206\u5225\u70ba\u5fc3\u7d5e\u75db\u548c\u5fc3\u529b\u8870\u7aed\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecponatinib\u6216asciminib\u8010\u85e5\/\u4e0d\u8010\u53d7\uff09\u7684CML-CP\u548c\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u6297\u816b\u7624\u4f5c\u7528\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002 Combination\u00a0of Third Generation\u00a0TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+\u00a0ALL Patients \u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216Blinatumomab\u7528\u65bc\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+ ALL\u6210\u4eba\u60a3\u8005 \u6458\u8981\u7de8\u865f\uff1aP427 \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76(Acute lymphoblastic leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1a\u9673\u4fca\u5091\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1aTKI\u6539\u5584\u4e86Ph+ ALL\u60a3\u8005\u7684\u9577\u671f\u9810\u5f8c\uff0c\u4f46TKI\u8010\u85e5\u554f\u984c\u4ecd\u7136\u662f\u4e00\u500b\u6311\u6230\u3002\u65e2\u5f80\u5831\u544a\u986f\u793a\uff0c\u7b2c\u4e09\u4ee3TKI Ponatinib\u806f\u5408\u5316\u7642\u5728\u4e09\u500b\u6708\u5167\u7684\u5b8c\u5168\u5206\u5b50\u5b78\u7de9\u89e3\u7387\uff08CMR\uff09\u53ef\u905475%\u3002\u5728\u6700\u8fd1\u7684\u4e00\u9805\u7814\u7a76\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408PDT-ALL-2016\u65b9\u6848\u4e00\u7dda\u6cbb\u7642Ph+ ALL\u986f\u793a\u51fa\u4e86\u826f\u597d\u7684\u7d50\u679c\uff0c\u6cbb\u7642\u5f8c\u7b2c90\u5929\u7684CMR\u7387\u70ba84.6%\u3002\u6b64\u5916\uff0cTKI\u806f\u5408blinatumomab\uff08BITE\uff09\u7684\u7121\u5316\u7642\u65b9\u6848\u5df2\u986f\u793a\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\uff08TKI+\u5316\u7642\uff09\u53ca\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408blinatumomab\uff08TKI+BITE\uff09\u7528\u65bc\u4e00\u7dda\u6cbb\u7642 Ph+ ALL \u7684\u81e8\u5e8a\u7642\u6548\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a2022\u5e741\u6708\u81f32023\u5e7412\u6708\uff0c\u7814\u7a76\u5165\u7d44\u4e8631\u4f8b\u65b0\u78ba\u8a3a\u7684Ph+ ALL\u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\uff0840mg\uff0c\u9694\u65e5\u4e00\u6b21\uff09\u806f\u5408\u5152\u7ae5\u555f\u767c\u5316\u7642\uff08n=19\uff1bPDT-ALL-2016\u65b9\u6848\uff09\u6216blinatumomab\uff08n=12\uff1b\u7d66\u85e52\u5468\uff0c 2\u5468\u7121\u6cbb\u7642\u9593\u6b47\u671f\uff09\u7684\u6cbb\u7642\u3002\u60a3\u8005\u4e2d\u4f4d\u5e74\u9f61\u70ba40\u6b72\uff0c15\u4f8b\uff0848.4%\uff09\u60a3\u8005\u5408\u4f751\u7a2e\u5408\u4f75\u75c7\uff0c8\u4f8b\uff0825.81%\uff09\u60a3\u8005\u67092\u7a2e\u4ee5\u4e0a\u5408\u4f75\u75c7\u3002 \u7642\u6548\u6578\u64da\uff1a\u4e2d\u4f4d\u96a8\u8a2a16\u500b\u6708\u5f8c\uff0c\u6240\u6709\u60a3\u8005\u5728\u63a5\u53d71\u500b\u6cbb\u7642\u9031\u671f\u5f8c\u5747\u7372\u5f97\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u3002\u7e3d\u968a\u5217\u4e2d\uff0c28\u4f8b\uff0890.3%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u5176\u4e2d\uff0cTKI+\u5316\u7642\u968a\u5217\u548cTKI+BITE\u968a\u5217\u5206\u5225\u670916\u4f8b\uff0884.2%\uff09\u548c12\u4f8b\uff08100.0%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u7e3d\u968a\u5217\u76841\u5e74\u7e3d\u751f\u5b58\uff08OS\uff09\u7387\u70ba93.1%\uff0c\u7121\u4e8b\u4ef6\u751f\u5b58\uff08EFS\uff09\u7387\u70ba78.4%\u3002TKI+\u5316\u7642\u968a\u5217\u76841\u5e74OS\u7387\u70ba96.2%\uff0cEFS\u7387\u70ba71.5%\u3002TKI+BITE\u968a\u5217\u76841\u5e74OS\u7387\u70ba 100.0%\uff0cEFS\u7387\u70ba90.0%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u572810\u4f8b\uff0832.3%\uff09\u60a3\u8005\u4e2d\u89c0\u5bdf\u5230\u4e0d\u826f\u4e8b\u4ef6\uff0c3\u4f8b\uff089.6%\uff09\u60a3\u8005\u5728\u6cbb\u7642\u671f\u9593\u767c\u751f\u611f\u67d3\u6027\u4f11\u514b\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u51fa\u73fe\u8f15\u5ea6\u80f0\u817a\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f\u8036\u6c0f\u80ba\u5b62\u5b50\u83cc\u80ba\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f2\u7d1a\u7d30\u80de\u56e0\u5b50\u91cb\u653e\u7d9c\u5408\u5f81\uff08CRS\uff09\uff1b1\u4f8b\uff083.2%\uff09\u60a3\u8005\u767c\u751f\u80ba\u6813\u585e\u3002 \u7d50\u8ad6\uff1a\u9019\u9805\u7814\u7a76\u5c0d\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216blinatumomab\u6cbb\u7642\u6210\u4ebaPh+ ALL\u60a3\u8005\u9032\u884c\u4e86\u8a55\u4f30\u3002\u5728\u5165\u7d44\u768431\u4f8b\u60a3\u8005\u4e2d\uff0c\u89c0\u5bdf\u5230\u4e86\u986f\u8457\u76841\u5e74\u751f\u5b58\u7387\u548cCMR \u7387\uff0c\u9019\u70ba\u63d0\u9ad8\u9577\u671f\u751f\u5b58\u7387\u5e36\u4f86\u4e86\u5e0c\u671b\u3002TKI+\u5316\u7642\u548cTKI+BITE\u968a\u5217\u90fd\u986f\u793a\u4e86\u826f\u597d\u7684\u81e8\u5e8a\u7d50\u679c\uff0c\u4e14TKI+BITE\u968a\u5217\u7684\u751f\u5b58\u6f5b\u529b\u512a\u65bcTKI+\u5316\u7642\u968a\u5217\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u5118\u7ba174.19%\u7684\u60a3\u8005\u6709\u81f3\u5c11\u4e00\u7a2e\u5408\u4f75\u75c7\uff0c\u4e2d\u4f4d\u5e74\u9f61\u905440\u6b72\uff0c\u5b89\u5168\u6027\u4ecd\u53ef\u63a5\u53d7\u3002 Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy \u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u6210\u5e74\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aP1862 \u5c55\u793a\u985e\u578b\uff1a\u96fb\u5b50\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1a\u65bc\u9732\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1a\u7b2c\u4e09\u4ee3TKI\u6539\u5584\u4e86TKI\u8010\u85e5\u7684CML\u60a3\u8005\u7684\u9810\u5f8c\u3002\u7136\u800c\uff0c\u95dc\u65bc\u63a5\u53d7\u5982\u5967\u96f7\u5df4\u66ff\u5c3c\u7b49\u7b2c\u4e09\u4ee3TKI\u7684\u6210\u5e74\u60a3\u8005\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40\u6578\u64da\u5f88\u5c11\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5CML\u60a3\u8005\u7684\u5065\u5eb7\u76f8\u95dc\u751f\u6d3b\u8cea\u91cf\uff08HRQoL\uff09\u3001\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\uff0c\u4e26\u78ba\u5b9a\u8207\u4e4b\u76f8\u95dc\u7684\u8b8a\u91cf\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a \u8a72\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\u4e2d\uff0c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u7684\u60a3\u8005\u5728\u57fa\u7dda\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u5b9a\u671f\u5b8c\u6210\u6b50\u6d32\u764c\u75c7\u7814\u7a76\u8207\u6cbb\u7642\u7d44\u7e54\uff08EORTC\uff09\u751f\u547d\u8cea\u91cf\u8a55\u4f30\u554f\u5377\uff08QLQ-C30\uff09\u3001\u7126\u616e\u81ea\u8a55\u91cf\u8868\uff08SAS\uff09\u548c\u6291\u9b31\u81ea\u8a55\u91cf\u8868\uff08SDS\uff09\u3002\u7814\u7a76\u901a\u904e\u57fa\u65bc\u7368\u7acb\u5de5\u4f5c\u76f8\u95dc\u77e9\u9663\u7684\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u7dda\u6027\u6a21\u578b\uff0c\u4f30\u8a08\u60a3\u8005\u5831\u544a\u7d50\u5c40\u96a8\u6642\u9593\u8b8a\u5316\u8da8\u52e2\uff0c\u4e26\u4f7f\u7528\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u6a21\u578b\u8a55\u4f30\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u548c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684\u6cbb\u7642\u53cd\u61c9\u5c0dHRQoL\u3001SAS\u548cSDS\u7684\u5f71\u97ff\u3002 \u672c\u7814\u7a76\u5171\u7d0d\u5165159\u4f8b\u8655\u65bcCP\u6216AP\u7684CML\u60a3\u8005\u3002\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f61\u70ba 42\uff0820-74\uff09\u6b72\u3002104\u4f8b\uff0865%\uff09\u60a3\u8005\u70ba\u7537\u6027\u3002\u5f9e\u78ba\u8a3aCML\u5230\u958b\u59cb\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u6642\u9593\u9593\u9694\u70ba5\uff080.3-23\uff09\u5e74\u300277\u4f8b\uff0848%\uff09\u60a3\u8005\u5728\u78ba\u8a3aCML\u5f8c\u76845\u5e74\u5167\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u3002\u6240\u6709\u60a3\u8005\u90fd\u5b8c\u6210\u4e86QLQ-C30\u554f\u5377\uff0c115\u4f8b\u60a3\u8005\u5b8c\u6210\u4e86SAS\u548cSDS\u554f\u5377\u3002 \u554f\u5377\u6578\u64da\uff1a \u6839\u64daEORTC QLQ-C30\u554f\u5377\u8a55\u4f30\uff0c\u57fa\u7dda\u6642\u6700\u56b4\u91cd\u76843\u7a2e\u75c7\u72c0\u8ca0\u64d4\u70ba\u7d93\u6fdf\u56f0\u96e3\u3001\u75b2\u52de\u548c\u5931\u7720\u3002\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\uff0c\u5305\u62ec\u6574\u9ad4\u5065\u5eb7\u3001\u8eab\u9ad4\u529f\u80fd\u3001\u60c5\u611f\u529f\u80fd\u3001\u75b2\u52de\u3001\u75bc\u75db\u3001\u547c\u5438\u56f0\u96e3\u3001\u8179\u7009\u548c\u7d93\u6fdf\u56f0\u96e3\u5728\u5167\u76848\u500b\u91cf\u8868\u9805\u76ee\u7372\u5f97\u986f\u8457\u6539\u5584\u3002\u6c92\u6709\u91cf\u8868\u9805\u76ee\u51fa\u73fe\u986f\u8457\u60e1\u5316\u3002\u5728\u591a\u8b8a\u91cf\u5206\u6790\u4e2d\uff0c\u5e74\u9f61&lt;40\u6b72\u8207\u66f4\u597d\u7684\u793e\u6703\u529f\u80fd\u6539\u5584\u76f8\u95dc\uff08p=0.021\uff09\uff1bCP\u60a3\u8005\uff08\u8207AP\u76f8\u6bd4\uff09\u547c\u5438\u56f0\u96e3\uff08p=0.028\uff09\u548c\u8179\u7009\uff08p=0.042\uff09\u5f97\u5230\u66f4\u597d\u7684\u6539\u5584\uff1b\u9054\u5230MMR\u5f8c\uff0c\u6574\u9ad4\u5065\u5eb7\uff08p=0.005\uff09\u3001\u5641\u5fc3\u5614\u5410\uff08p=0.009\uff09\u548c\u8179\u7009\uff08p=0.001\uff09\u90fd\u7372\u5f97\u66f4\u597d\u7684\u6539\u5584\u3002 \u57fa\u7dda\u6642\uff0c\u6839\u64daSAS\u8a55\u5206\uff0c\u670996\u4f8b\uff0884%\uff09\u60a3\u8005\u6b63\u5e38\uff0c19\u4f8b\uff0816%\uff09\u60a3\u8005\u6709\u8f15\u5ea6\u6216\u4e2d\u5ea6\u7126\u616e\u75c7\u72c0\u3002\u6839\u64daSDS\u8a55\u5206\uff0c64\u4f8b\uff0856%\uff09\u60a3\u8005\u6b63\u5e38\uff1b37\u4f8b\uff0832%\uff09\u6709\u8f15\u5ea6\u6291\u9b31\u75c7\u72c0\uff0c14\u4f8b\uff0812%\uff09\u6709\u4e2d\u5ea6\u6216\u91cd\u5ea6\u6291\u9b31\u75c7\u72c0\u3002SAS\u8a55\u5206\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u96a8\u6642\u9593\u63a8\u9032\u986f\u8457\u964d\u4f4e\uff08p&lt;0.001\uff09\uff0c\u800cSDS\u8a55\u5206\u6c92\u6709\u986f\u8457\u8b8a\u5316\u3002\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642 \u7684\u7b2c36\u500b\u6708\uff0c\u5206\u5225\u670978\u4f8b\uff0895%\uff09\u548c48\u4f8b\uff0859%\uff09\u60a3\u8005\u6839\u64daSAS\u548cSDS\u554f\u5377\u8a55\u4f30\u7d50\u679c\u88ab\u8a8d\u5b9a\u70ba\u6c92\u6709\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\u3002\u6c92\u6709\u767c\u73fe\u4efb\u4f55\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u5f71\u97ffSAS\u8a55\u5206\u8b8a\u5316\u7684\u8b8a\u91cf\u3002 \u7d50\u8ad6\uff1aTKI\u8010\u85e5CML\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684HRQoL\u548c\u7126\u616e\u75c7\u72c0\u96a8\u6642\u9593\u7684\u5ef6\u9577\u6709\u986f\u8457\u6539\u5584\u3002\u5e74\u9f61\u8f03\u5c0f\uff0c\u8655\u65bcCP\u671f\uff0c\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u9054\u5230MMR\u7684\u60a3\u8005\u7684HRQoL\u6539\u5584\u60c5\u6cc1\u66f4\u597d\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u570b\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u7684\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9e\u76db\u91ab\u85e5\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\u3002 \u4e9e\u76db\u91ab\u85e5\u64c1\u6709\u81ea\u4e3b\u69cb\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u85e5\u7269\u8a2d\u8a08\u5e73\u53f0\uff0c\u8655\u65bc\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u85e5\u7814\u767c\u7684\u5168\u7403\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u64c1\u67099\u500b\u5df2\u9032\u5165\u81e8\u5e8a\u958b\u767c\u968e\u6bb5\u76841\u985e\u5c0f\u5206\u5b50\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP\u6216MDM2-p53\u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\uff0c\u70ba\u5168\u7403\u552f\u4e00\u5728\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u9818\u57df\u5747\u6709\u81e8\u5e8a\u958b\u767c\u54c1\u7a2e\u7684\u5275\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u570b\u3001\u7f8e\u570b\u3001\u6fb3\u5927\u5229\u4e9e\u53ca\u6b50\u6d32\u958b\u5c5540\u591a\u9805\u81e8\u5e8a\u8a66\u9a57\uff0c\u5176\u4e2d5\u9805\u70ba\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u3002 \u7528\u65bc\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u7a2e\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u66fe\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u65b0\u85e5\u5be9\u8a55\u4e2d\u5fc3\uff08CDE\uff09\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u548c\u7a81\u7834\u6027\u6cbb\u7642\u54c1\u7a2e\uff0c\u4e26\u5df2\u5728\u4e2d\u570b\u7372\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u500b\u4e0a\u5e02\u54c1\u7a2e\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u5df2\u88ab\u6210\u529f\u7d0d\u5165\u300a\u570b\u5bb6\u57fa\u672c\u91ab\u7642\u4fdd\u96aa\u3001\u5de5\u50b7\u4fdd\u96aa\u548c\u751f\u80b2\u4fdd\u96aa\u85e5\u54c1\u76ee\u9304(2022\u5e74)\u300b\u3002\u8a72\u54c1\u7a2e\u9084\u7372\u5f97\u4e86\u7f8e\u570bFDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u3001\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3001\u4ee5\u53ca\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u500b\u5728\u7814\u65b0\u85e5\u7372\u5f9716\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u516c\u53f8\u5148\u5f8c\u627f\u64d4\u591a\u9805\u570b\u5bb6\u79d1\u6280\u91cd\u5927\u5c08\u9805\uff0c\u5176\u4e2d\u300c\u91cd\u5927\u65b0\u85e5\u5275\u88fd\u300d\u5c08\u98055\u9805\uff0c\u5305\u62ec1\u9805\u300c\u4f01\u696d\u5275\u65b0\u85e5\u7269\u5b75\u5316\u57fa\u5730\u300d\u53ca4\u9805\u300c\u5275\u65b0\u85e5\u7269\u7814\u767c\u300d\uff0c\u53e6\u5916\u627f\u64d4\u300c\u91cd\u5927\u50b3\u67d3\u75c5\u9632\u6cbb\u300d\u5c08\u98051\u9805\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207UNITY\u3001MD Anderson\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u7b49\u9818\u5148\u7684\u751f\u7269\u6280\u8853\u53ca\u91ab\u85e5\u516c\u53f8\u3001\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u8c50\u5bcc\u7684\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u7d93\u9a57\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u540c\u6642\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6a19\u6e96\u6253\u9020\u5f8c\u671f\u7684\u5546\u696d\u5316\u751f\u7522\u53ca\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u8207\u672c\u6587\u4f5c\u51fa\u8a72\u9673\u8ff0\u7576\u65e5\u7684\u4e8b\u4ef6\u6216\u8cc7\u6599\u6709\u95dc\u3002\u9664\u6cd5\u5f8b\u898f\u5b9a\u5916\uff0c\u65bc\u4f5c\u51fa\u524d\u77bb\u6027\u9673\u8ff0\u7576\u65e5\u4e4b\u5f8c\uff0c\u7121\u8ad6\u662f\u5426\u51fa\u73fe\u65b0\u8cc7\u6599\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u6211\u5011\u4e26\u7121\u8cac\u4efb\u66f4\u65b0\u6216\u516c\u958b\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u9810\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8acb\u7d30\u95b1\u672c\u6587\uff0c\u4e26\u7406\u89e3\u6211\u5011\u7684\u5be6\u969b\u672a\u4f86\u696d\u7e3e\u6216\u8868\u73fe\u53ef\u80fd\u8207\u9810\u671f\u6709\u91cd\u5927\u5dee\u7570\u3002\u672c\u6587\u5167\u6240\u6709\u9673\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u767c\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u4f86\u767c\u5c55\u800c\u51fa\u73fe\u8b8a\u52d5\u3002<\/p>\n","protected":false},"author":0,"featured_media":19870,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_generate-full-width-content":"","spay_email":"","footnotes":""},"categories":[1],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df\" \/>\n<meta property=\"og:description\" content=\"\u4e2d\u570b\u8607\u5dde\u548c\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e2024\u5e746\u670818\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff1b\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u7684\u4e09\u9805\u7814\u7a76\u6700\u65b0\u6578\u64da\uff0c\u5df2\u57282024\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703\uff08EHA 2024\uff09\u4e0a\u4ee5\u58c1\u5831\u5f62\u5f0f\u516c\u4f48\u3002 \u5176\u4e2d\uff0c\u57282023\u5e74\u7f8e\u570b\u8840\u6db2\u5b78\u6703\u5e74\u6703\u516c\u4f48\u7684\u6578\u64da\u57fa\u790e\u4e0a\uff0c\u516c\u53f8\u66f4\u65b0\u4e86\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7814\u7a76\u7684\u4e2d\u4f4d1\u5e74\u96a8\u8a2a\u6578\u64da\u3002\u7d50\u679c\u986f\u793a\u5c0d\u65bc\u7d93\u904e\u591a\u500bTKI\u6cbb\u7642\uff08\u5305\u62ec\u5c0dponatinib\u6216\/\u548casciminib\u8010\u85e5\uff09\uff0c\u4f34\u6709\u6216\u4e0d\u4f34\u6709T315I\u7a81\u8b8a\uff0c\u8010\u7acb\u514b\u00ae\u90fd\u8868\u73fe\u51fa\u512a\u7570\u6301\u7e8c\u7684\u81e8\u5e8a\u7642\u6548\uff0c\u60a3\u8005\u9577\u671f\u85e5\u7269\u8010\u53d7\u6027\u826f\u597d\u3002 \u8a72\u9805\u81e8\u5e8a\u7814\u7a76\u7684\u4e3b\u8981\u7814\u7a76\u8005\u3001MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u767d\u8840\u75c5\u79d1\u7684Elia Jabbour\u535a\u58eb\u8868\u793a\uff1a\u300c\u7814\u7a76\u8868\u660e\uff0c\u8010\u7acb\u514b\u00ae\u5728\u91dd\u5c0d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684CML\u548cPh+ ALL\uff08\u5305\u62ec\u5c0dponatinib\u548casciminib\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff09\u7684\u60a3\u8005\u6642\uff0c\u5177\u6709\u986f\u8457\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002\u9019\u610f\u5473\u8457\u8010\u7acb\u514b\u00ae\u6709\u6f5b\u529b\u70ba\u9019\u4e00\u5177\u6709\u6311\u6230\u6027\u7684\u60a3\u8005\u7fa4\u9ad4\u63d0\u4f9b\u6709\u50f9\u503c\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u9700\u8981\u901a\u904e\u9577\u671f\u7814\u7a76\u9032\u4e00\u6b65\u9a57\u8b49\u5176\u81e8\u5e8a\u512a\u52e2\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4ee5\u5f80\u9032\u5c55\u548c\u672c\u6b21\u5728EHA\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u6700\u65b0\u6578\u64da\uff0c\u518d\u6b21\u8b49\u660e\u4e86\u8010\u7acb\u514b\u00ae\u5728ponatinib\u548casciminib\u8010\u85e5\u60a3\u8005\u4e2d\u7684\u5de8\u5927\u6f5b\u529b\u3002\u6211\u5011\u5c07\u52a0\u5feb\u9019\u4e00\u5168\u7403\u300eBest-in-class\u300f\u7522\u54c1\u7684\u81e8\u5e8a\u958b\u767c\uff0c\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u8010\u7acb\u514b\u00ae\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u5168\u7403\u5c64\u9762\u300cBest-in-class\u300d\u85e5\u7269\u3002\u4f5c\u70ba\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u8a72\u7522\u54c1\u76ee\u524d\u5df2\u6709\u5169\u9805\u9069\u61c9\u75c7\u7372\u6279\uff0c\u5206\u5225\u70ba\u6cbb\u7642\u4efb\u4f55TKI\u8010\u85e5\u3001\u4e26\u4f34\u6709T315I\u7a81\u8b8a\u7684CML\u6162\u6027\u671f\uff08-CP\uff09\u548c\u52a0\u901f\u671f\uff08-AP\uff09\u7684\u6210\u5e74\u60a3\u8005\uff1b\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8010\u7acb\u514b\u00ae\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u6709\u4e00\u9805\u6cbb\u7642\u521d\u6cbbPh+ ALL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\uff0c\u610f\u5473\u8457\u5176\u6709\u671b\u6210\u70ba\u570b\u5167\u9996\u500b\u7372\u6279\u7684\u7528\u65bcPh+ ALL\u4e00\u7dda\u6cbb\u7642\u7684TKI\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002\u4e9e\u76db\u91ab\u85e5\u9084\u5728\u672c\u5c46\u5927\u6703\u4e0a\u516c\u4f48\u4e86Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7684\u6700\u65b0\u7814\u7a76\u9032\u5c55\u3002 \u8010\u7acb\u514b\u00ae\u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff1a Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u5c0dPonatinib\u548cAsciminib\u7684\u8010\u85e5 \u6458\u8981\u7de8\u865f\uff1aP722 \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1aElias Jabbour\u535a\u58eb\uff0c\u5fb7\u5dde\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u4e00\u6b3e\u65b0\u578b\u5f37\u6548BCR::ABL1 TKI\uff0c\u76ee\u524d\u5df2\u6709\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u6578\u64da\u8b49\u5be6\u5176\u5728CML\u6216Ph+ ALL\u7684\u60a3\u8005\u4e2d\u5177\u6709\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u9019\u662f\u4e00\u9805\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecPonatinib\u548cAsciminib\uff09\u7684CML\u6216Ph+ ALL\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a\u622a\u81f32024\u5e741\u67082\u65e5\uff0c\u672c\u7814\u7a76\u5171\u7d0d\u516580\u4f8b\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\u60a3\u8005\uff0c\u5305\u62ec62\u4f8bCML-CP\u548c18\u4f8b\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\uff08\u5305\u62ecCML-AP, CML-BP, \u548cPh+ ALL\uff09\u60a3\u8005\u3002\u60a3\u8005\u96a8\u6a5f\u5206\u914d\u81f330mg\u300140mg\u548c50 mg\u5291\u91cf\u7d44\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u63a1\u7528\u9694\u5929\u4e00\u6b21\uff08QOD\uff09\u53e3\u670d\u7d66\u85e5\u65b9\u6848\uff0c\u6bcf28\u5929\u70ba\u4e00\u500b\u7d66\u85e5\u9031\u671f\u3002 \u7642\u6548\u6578\u64da\uff1a 1)\u00a0 CML-CP\u60a3\u8005\uff1a 31\/51\uff0860.8%\uff09\u60a3\u8005\u7372\u5f97\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\uff0c25\/59\uff0842.4%\uff09\u60a3\u8005\u7372\u5f97\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u3002\u4e14\u53cd\u61c9\u7387\u8207\u662f\u5426\u4f34\u6709T315I\u7a81\u8b8a\u7121\u5dee\u7570\uff1b\u00a0 \u65e2\u5f80ponatinib\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u4e2d\uff0c\u517115\/26\uff0857.7%\uff09\u7372\u5f97CCyR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e5\u60a3\u800510\/19 [52.6%]\u4f8b\u548c\u4e0d\u8010\u53d7\u60a3\u80053\/4[75.0%]\u4f8b\uff09\uff1b\u517111\/30\uff0836.7%\uff09\u7372\u5f97MMR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e59\/21[42.9%]\u548c\u4e0d\u8010\u53d71\/6[16.7%]\uff09\uff1b\u00a0 \u65e2\u5f80Asciminib\u6cbb\u7642\u8010\u85e5\u7684\u60a3\u8005\u4e2d\uff0c4\/8\uff0850.0%\uff09\u7372\u5f97CCyR, 4\/12\uff0833.3%\uff09\u7372\u5f97MMR\u3002 2)\u00a0 \u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\uff1a 3\/14\uff0821.4%\uff09\u60a3\u8005\u7372\u5f97CCyR\uff0c3\/17\uff0817.6%\uff09\u60a3\u8005\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a 72\u4f8b\uff0890.0%\uff09\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u7d93\u6b77\u4e86\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u5176\u4e2d\u5927\u90e8\u5206\u70ba\u8f15\u5ea6\u6216\u4e2d\u5ea6\uff1b \u8f03\u5e38\u898b\u7684\u22653\u7d1aTEAEs\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0817.5%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0812.5%\uff09\u548c\u8840\u808c\u9178\u78f7\u9178\u6fc0\u9176\u5347\u9ad8\uff0812.5%\uff09\uff1b\u767c\u751f\u5728\u22653\u4f8b\uff083.8%\uff09\u60a3\u8005\u4e2d\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\u5305\u62ec\u623f\u986b\u3001COVID-19\u611f\u67d3\u3001\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u548c\u8178\u6897\u963b\uff1b\u7121\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAE\uff09\u5c0e\u81f4\u60a3\u8005\u6b7b\u4ea1\u3002\u5169\u4f8b\uff082.5%\uff09\u60a3\u8005\u767c\u751f1\u7d1a\u8207\u6cbb\u7642\u76f8\u95dc\u7684\u52d5\u8108\u8840\u7ba1\u9589\u585e\u4e8b\u4ef6\uff0c\u5206\u5225\u70ba\u5fc3\u7d5e\u75db\u548c\u5fc3\u529b\u8870\u7aed\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecponatinib\u6216asciminib\u8010\u85e5\/\u4e0d\u8010\u53d7\uff09\u7684CML-CP\u548c\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u6297\u816b\u7624\u4f5c\u7528\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002 Combination\u00a0of Third Generation\u00a0TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+\u00a0ALL Patients \u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216Blinatumomab\u7528\u65bc\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+ ALL\u6210\u4eba\u60a3\u8005 \u6458\u8981\u7de8\u865f\uff1aP427 \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76(Acute lymphoblastic leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1a\u9673\u4fca\u5091\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1aTKI\u6539\u5584\u4e86Ph+ ALL\u60a3\u8005\u7684\u9577\u671f\u9810\u5f8c\uff0c\u4f46TKI\u8010\u85e5\u554f\u984c\u4ecd\u7136\u662f\u4e00\u500b\u6311\u6230\u3002\u65e2\u5f80\u5831\u544a\u986f\u793a\uff0c\u7b2c\u4e09\u4ee3TKI Ponatinib\u806f\u5408\u5316\u7642\u5728\u4e09\u500b\u6708\u5167\u7684\u5b8c\u5168\u5206\u5b50\u5b78\u7de9\u89e3\u7387\uff08CMR\uff09\u53ef\u905475%\u3002\u5728\u6700\u8fd1\u7684\u4e00\u9805\u7814\u7a76\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408PDT-ALL-2016\u65b9\u6848\u4e00\u7dda\u6cbb\u7642Ph+ ALL\u986f\u793a\u51fa\u4e86\u826f\u597d\u7684\u7d50\u679c\uff0c\u6cbb\u7642\u5f8c\u7b2c90\u5929\u7684CMR\u7387\u70ba84.6%\u3002\u6b64\u5916\uff0cTKI\u806f\u5408blinatumomab\uff08BITE\uff09\u7684\u7121\u5316\u7642\u65b9\u6848\u5df2\u986f\u793a\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\uff08TKI+\u5316\u7642\uff09\u53ca\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408blinatumomab\uff08TKI+BITE\uff09\u7528\u65bc\u4e00\u7dda\u6cbb\u7642 Ph+ ALL \u7684\u81e8\u5e8a\u7642\u6548\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a2022\u5e741\u6708\u81f32023\u5e7412\u6708\uff0c\u7814\u7a76\u5165\u7d44\u4e8631\u4f8b\u65b0\u78ba\u8a3a\u7684Ph+ ALL\u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\uff0840mg\uff0c\u9694\u65e5\u4e00\u6b21\uff09\u806f\u5408\u5152\u7ae5\u555f\u767c\u5316\u7642\uff08n=19\uff1bPDT-ALL-2016\u65b9\u6848\uff09\u6216blinatumomab\uff08n=12\uff1b\u7d66\u85e52\u5468\uff0c 2\u5468\u7121\u6cbb\u7642\u9593\u6b47\u671f\uff09\u7684\u6cbb\u7642\u3002\u60a3\u8005\u4e2d\u4f4d\u5e74\u9f61\u70ba40\u6b72\uff0c15\u4f8b\uff0848.4%\uff09\u60a3\u8005\u5408\u4f751\u7a2e\u5408\u4f75\u75c7\uff0c8\u4f8b\uff0825.81%\uff09\u60a3\u8005\u67092\u7a2e\u4ee5\u4e0a\u5408\u4f75\u75c7\u3002 \u7642\u6548\u6578\u64da\uff1a\u4e2d\u4f4d\u96a8\u8a2a16\u500b\u6708\u5f8c\uff0c\u6240\u6709\u60a3\u8005\u5728\u63a5\u53d71\u500b\u6cbb\u7642\u9031\u671f\u5f8c\u5747\u7372\u5f97\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u3002\u7e3d\u968a\u5217\u4e2d\uff0c28\u4f8b\uff0890.3%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u5176\u4e2d\uff0cTKI+\u5316\u7642\u968a\u5217\u548cTKI+BITE\u968a\u5217\u5206\u5225\u670916\u4f8b\uff0884.2%\uff09\u548c12\u4f8b\uff08100.0%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u7e3d\u968a\u5217\u76841\u5e74\u7e3d\u751f\u5b58\uff08OS\uff09\u7387\u70ba93.1%\uff0c\u7121\u4e8b\u4ef6\u751f\u5b58\uff08EFS\uff09\u7387\u70ba78.4%\u3002TKI+\u5316\u7642\u968a\u5217\u76841\u5e74OS\u7387\u70ba96.2%\uff0cEFS\u7387\u70ba71.5%\u3002TKI+BITE\u968a\u5217\u76841\u5e74OS\u7387\u70ba 100.0%\uff0cEFS\u7387\u70ba90.0%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u572810\u4f8b\uff0832.3%\uff09\u60a3\u8005\u4e2d\u89c0\u5bdf\u5230\u4e0d\u826f\u4e8b\u4ef6\uff0c3\u4f8b\uff089.6%\uff09\u60a3\u8005\u5728\u6cbb\u7642\u671f\u9593\u767c\u751f\u611f\u67d3\u6027\u4f11\u514b\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u51fa\u73fe\u8f15\u5ea6\u80f0\u817a\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f\u8036\u6c0f\u80ba\u5b62\u5b50\u83cc\u80ba\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f2\u7d1a\u7d30\u80de\u56e0\u5b50\u91cb\u653e\u7d9c\u5408\u5f81\uff08CRS\uff09\uff1b1\u4f8b\uff083.2%\uff09\u60a3\u8005\u767c\u751f\u80ba\u6813\u585e\u3002 \u7d50\u8ad6\uff1a\u9019\u9805\u7814\u7a76\u5c0d\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216blinatumomab\u6cbb\u7642\u6210\u4ebaPh+ ALL\u60a3\u8005\u9032\u884c\u4e86\u8a55\u4f30\u3002\u5728\u5165\u7d44\u768431\u4f8b\u60a3\u8005\u4e2d\uff0c\u89c0\u5bdf\u5230\u4e86\u986f\u8457\u76841\u5e74\u751f\u5b58\u7387\u548cCMR \u7387\uff0c\u9019\u70ba\u63d0\u9ad8\u9577\u671f\u751f\u5b58\u7387\u5e36\u4f86\u4e86\u5e0c\u671b\u3002TKI+\u5316\u7642\u548cTKI+BITE\u968a\u5217\u90fd\u986f\u793a\u4e86\u826f\u597d\u7684\u81e8\u5e8a\u7d50\u679c\uff0c\u4e14TKI+BITE\u968a\u5217\u7684\u751f\u5b58\u6f5b\u529b\u512a\u65bcTKI+\u5316\u7642\u968a\u5217\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u5118\u7ba174.19%\u7684\u60a3\u8005\u6709\u81f3\u5c11\u4e00\u7a2e\u5408\u4f75\u75c7\uff0c\u4e2d\u4f4d\u5e74\u9f61\u905440\u6b72\uff0c\u5b89\u5168\u6027\u4ecd\u53ef\u63a5\u53d7\u3002 Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy \u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u6210\u5e74\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aP1862 \u5c55\u793a\u985e\u578b\uff1a\u96fb\u5b50\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1a\u65bc\u9732\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1a\u7b2c\u4e09\u4ee3TKI\u6539\u5584\u4e86TKI\u8010\u85e5\u7684CML\u60a3\u8005\u7684\u9810\u5f8c\u3002\u7136\u800c\uff0c\u95dc\u65bc\u63a5\u53d7\u5982\u5967\u96f7\u5df4\u66ff\u5c3c\u7b49\u7b2c\u4e09\u4ee3TKI\u7684\u6210\u5e74\u60a3\u8005\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40\u6578\u64da\u5f88\u5c11\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5CML\u60a3\u8005\u7684\u5065\u5eb7\u76f8\u95dc\u751f\u6d3b\u8cea\u91cf\uff08HRQoL\uff09\u3001\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\uff0c\u4e26\u78ba\u5b9a\u8207\u4e4b\u76f8\u95dc\u7684\u8b8a\u91cf\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a \u8a72\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\u4e2d\uff0c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u7684\u60a3\u8005\u5728\u57fa\u7dda\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u5b9a\u671f\u5b8c\u6210\u6b50\u6d32\u764c\u75c7\u7814\u7a76\u8207\u6cbb\u7642\u7d44\u7e54\uff08EORTC\uff09\u751f\u547d\u8cea\u91cf\u8a55\u4f30\u554f\u5377\uff08QLQ-C30\uff09\u3001\u7126\u616e\u81ea\u8a55\u91cf\u8868\uff08SAS\uff09\u548c\u6291\u9b31\u81ea\u8a55\u91cf\u8868\uff08SDS\uff09\u3002\u7814\u7a76\u901a\u904e\u57fa\u65bc\u7368\u7acb\u5de5\u4f5c\u76f8\u95dc\u77e9\u9663\u7684\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u7dda\u6027\u6a21\u578b\uff0c\u4f30\u8a08\u60a3\u8005\u5831\u544a\u7d50\u5c40\u96a8\u6642\u9593\u8b8a\u5316\u8da8\u52e2\uff0c\u4e26\u4f7f\u7528\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u6a21\u578b\u8a55\u4f30\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u548c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684\u6cbb\u7642\u53cd\u61c9\u5c0dHRQoL\u3001SAS\u548cSDS\u7684\u5f71\u97ff\u3002 \u672c\u7814\u7a76\u5171\u7d0d\u5165159\u4f8b\u8655\u65bcCP\u6216AP\u7684CML\u60a3\u8005\u3002\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f61\u70ba 42\uff0820-74\uff09\u6b72\u3002104\u4f8b\uff0865%\uff09\u60a3\u8005\u70ba\u7537\u6027\u3002\u5f9e\u78ba\u8a3aCML\u5230\u958b\u59cb\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u6642\u9593\u9593\u9694\u70ba5\uff080.3-23\uff09\u5e74\u300277\u4f8b\uff0848%\uff09\u60a3\u8005\u5728\u78ba\u8a3aCML\u5f8c\u76845\u5e74\u5167\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u3002\u6240\u6709\u60a3\u8005\u90fd\u5b8c\u6210\u4e86QLQ-C30\u554f\u5377\uff0c115\u4f8b\u60a3\u8005\u5b8c\u6210\u4e86SAS\u548cSDS\u554f\u5377\u3002 \u554f\u5377\u6578\u64da\uff1a \u6839\u64daEORTC QLQ-C30\u554f\u5377\u8a55\u4f30\uff0c\u57fa\u7dda\u6642\u6700\u56b4\u91cd\u76843\u7a2e\u75c7\u72c0\u8ca0\u64d4\u70ba\u7d93\u6fdf\u56f0\u96e3\u3001\u75b2\u52de\u548c\u5931\u7720\u3002\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\uff0c\u5305\u62ec\u6574\u9ad4\u5065\u5eb7\u3001\u8eab\u9ad4\u529f\u80fd\u3001\u60c5\u611f\u529f\u80fd\u3001\u75b2\u52de\u3001\u75bc\u75db\u3001\u547c\u5438\u56f0\u96e3\u3001\u8179\u7009\u548c\u7d93\u6fdf\u56f0\u96e3\u5728\u5167\u76848\u500b\u91cf\u8868\u9805\u76ee\u7372\u5f97\u986f\u8457\u6539\u5584\u3002\u6c92\u6709\u91cf\u8868\u9805\u76ee\u51fa\u73fe\u986f\u8457\u60e1\u5316\u3002\u5728\u591a\u8b8a\u91cf\u5206\u6790\u4e2d\uff0c\u5e74\u9f61&lt;40\u6b72\u8207\u66f4\u597d\u7684\u793e\u6703\u529f\u80fd\u6539\u5584\u76f8\u95dc\uff08p=0.021\uff09\uff1bCP\u60a3\u8005\uff08\u8207AP\u76f8\u6bd4\uff09\u547c\u5438\u56f0\u96e3\uff08p=0.028\uff09\u548c\u8179\u7009\uff08p=0.042\uff09\u5f97\u5230\u66f4\u597d\u7684\u6539\u5584\uff1b\u9054\u5230MMR\u5f8c\uff0c\u6574\u9ad4\u5065\u5eb7\uff08p=0.005\uff09\u3001\u5641\u5fc3\u5614\u5410\uff08p=0.009\uff09\u548c\u8179\u7009\uff08p=0.001\uff09\u90fd\u7372\u5f97\u66f4\u597d\u7684\u6539\u5584\u3002 \u57fa\u7dda\u6642\uff0c\u6839\u64daSAS\u8a55\u5206\uff0c\u670996\u4f8b\uff0884%\uff09\u60a3\u8005\u6b63\u5e38\uff0c19\u4f8b\uff0816%\uff09\u60a3\u8005\u6709\u8f15\u5ea6\u6216\u4e2d\u5ea6\u7126\u616e\u75c7\u72c0\u3002\u6839\u64daSDS\u8a55\u5206\uff0c64\u4f8b\uff0856%\uff09\u60a3\u8005\u6b63\u5e38\uff1b37\u4f8b\uff0832%\uff09\u6709\u8f15\u5ea6\u6291\u9b31\u75c7\u72c0\uff0c14\u4f8b\uff0812%\uff09\u6709\u4e2d\u5ea6\u6216\u91cd\u5ea6\u6291\u9b31\u75c7\u72c0\u3002SAS\u8a55\u5206\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u96a8\u6642\u9593\u63a8\u9032\u986f\u8457\u964d\u4f4e\uff08p&lt;0.001\uff09\uff0c\u800cSDS\u8a55\u5206\u6c92\u6709\u986f\u8457\u8b8a\u5316\u3002\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642 \u7684\u7b2c36\u500b\u6708\uff0c\u5206\u5225\u670978\u4f8b\uff0895%\uff09\u548c48\u4f8b\uff0859%\uff09\u60a3\u8005\u6839\u64daSAS\u548cSDS\u554f\u5377\u8a55\u4f30\u7d50\u679c\u88ab\u8a8d\u5b9a\u70ba\u6c92\u6709\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\u3002\u6c92\u6709\u767c\u73fe\u4efb\u4f55\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u5f71\u97ffSAS\u8a55\u5206\u8b8a\u5316\u7684\u8b8a\u91cf\u3002 \u7d50\u8ad6\uff1aTKI\u8010\u85e5CML\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684HRQoL\u548c\u7126\u616e\u75c7\u72c0\u96a8\u6642\u9593\u7684\u5ef6\u9577\u6709\u986f\u8457\u6539\u5584\u3002\u5e74\u9f61\u8f03\u5c0f\uff0c\u8655\u65bcCP\u671f\uff0c\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u9054\u5230MMR\u7684\u60a3\u8005\u7684HRQoL\u6539\u5584\u60c5\u6cc1\u66f4\u597d\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u570b\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u7684\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9e\u76db\u91ab\u85e5\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\u3002 \u4e9e\u76db\u91ab\u85e5\u64c1\u6709\u81ea\u4e3b\u69cb\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u85e5\u7269\u8a2d\u8a08\u5e73\u53f0\uff0c\u8655\u65bc\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u85e5\u7814\u767c\u7684\u5168\u7403\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u64c1\u67099\u500b\u5df2\u9032\u5165\u81e8\u5e8a\u958b\u767c\u968e\u6bb5\u76841\u985e\u5c0f\u5206\u5b50\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP\u6216MDM2-p53\u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\uff0c\u70ba\u5168\u7403\u552f\u4e00\u5728\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u9818\u57df\u5747\u6709\u81e8\u5e8a\u958b\u767c\u54c1\u7a2e\u7684\u5275\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u570b\u3001\u7f8e\u570b\u3001\u6fb3\u5927\u5229\u4e9e\u53ca\u6b50\u6d32\u958b\u5c5540\u591a\u9805\u81e8\u5e8a\u8a66\u9a57\uff0c\u5176\u4e2d5\u9805\u70ba\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u3002 \u7528\u65bc\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u7a2e\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u66fe\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u65b0\u85e5\u5be9\u8a55\u4e2d\u5fc3\uff08CDE\uff09\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u548c\u7a81\u7834\u6027\u6cbb\u7642\u54c1\u7a2e\uff0c\u4e26\u5df2\u5728\u4e2d\u570b\u7372\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u500b\u4e0a\u5e02\u54c1\u7a2e\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u5df2\u88ab\u6210\u529f\u7d0d\u5165\u300a\u570b\u5bb6\u57fa\u672c\u91ab\u7642\u4fdd\u96aa\u3001\u5de5\u50b7\u4fdd\u96aa\u548c\u751f\u80b2\u4fdd\u96aa\u85e5\u54c1\u76ee\u9304(2022\u5e74)\u300b\u3002\u8a72\u54c1\u7a2e\u9084\u7372\u5f97\u4e86\u7f8e\u570bFDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u3001\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3001\u4ee5\u53ca\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u500b\u5728\u7814\u65b0\u85e5\u7372\u5f9716\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u516c\u53f8\u5148\u5f8c\u627f\u64d4\u591a\u9805\u570b\u5bb6\u79d1\u6280\u91cd\u5927\u5c08\u9805\uff0c\u5176\u4e2d\u300c\u91cd\u5927\u65b0\u85e5\u5275\u88fd\u300d\u5c08\u98055\u9805\uff0c\u5305\u62ec1\u9805\u300c\u4f01\u696d\u5275\u65b0\u85e5\u7269\u5b75\u5316\u57fa\u5730\u300d\u53ca4\u9805\u300c\u5275\u65b0\u85e5\u7269\u7814\u767c\u300d\uff0c\u53e6\u5916\u627f\u64d4\u300c\u91cd\u5927\u50b3\u67d3\u75c5\u9632\u6cbb\u300d\u5c08\u98051\u9805\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207UNITY\u3001MD Anderson\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u7b49\u9818\u5148\u7684\u751f\u7269\u6280\u8853\u53ca\u91ab\u85e5\u516c\u53f8\u3001\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u8c50\u5bcc\u7684\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u7d93\u9a57\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u540c\u6642\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6a19\u6e96\u6253\u9020\u5f8c\u671f\u7684\u5546\u696d\u5316\u751f\u7522\u53ca\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u8207\u672c\u6587\u4f5c\u51fa\u8a72\u9673\u8ff0\u7576\u65e5\u7684\u4e8b\u4ef6\u6216\u8cc7\u6599\u6709\u95dc\u3002\u9664\u6cd5\u5f8b\u898f\u5b9a\u5916\uff0c\u65bc\u4f5c\u51fa\u524d\u77bb\u6027\u9673\u8ff0\u7576\u65e5\u4e4b\u5f8c\uff0c\u7121\u8ad6\u662f\u5426\u51fa\u73fe\u65b0\u8cc7\u6599\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u6211\u5011\u4e26\u7121\u8cac\u4efb\u66f4\u65b0\u6216\u516c\u958b\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u9810\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8acb\u7d30\u95b1\u672c\u6587\uff0c\u4e26\u7406\u89e3\u6211\u5011\u7684\u5be6\u969b\u672a\u4f86\u696d\u7e3e\u6216\u8868\u73fe\u53ef\u80fd\u8207\u9810\u671f\u6709\u91cd\u5927\u5dee\u7570\u3002\u672c\u6587\u5167\u6240\u6709\u9673\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u767c\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u4f86\u767c\u5c55\u800c\u51fa\u73fe\u8b8a\u52d5\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869\" \/>\n<meta property=\"og:site_name\" content=\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-17T20:15:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277\",\"datePublished\":\"2024-06-17T20:15:00+00:00\",\"dateModified\":\"2024-06-17T20:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869\"},\"wordCount\":305,\"publisher\":{\"@id\":\"https:\/\/www.franchise.com.hk\/en#organization\"},\"articleSection\":[\"\u672a\u5206\u985e\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869\",\"url\":\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869\",\"name\":\"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"isPartOf\":{\"@id\":\"https:\/\/www.franchise.com.hk\/en#website\"},\"datePublished\":\"2024-06-17T20:15:00+00:00\",\"dateModified\":\"2024-06-17T20:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\/\/www.franchise.com.hk\/en\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.franchise.com.hk\/en#website\",\"url\":\"https:\/\/www.franchise.com.hk\/en\",\"name\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"description\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df | Franchise HK\",\"publisher\":{\"@id\":\"https:\/\/www.franchise.com.hk\/en#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.franchise.com.hk\/en?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.franchise.com.hk\/en#organization\",\"name\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"url\":\"https:\/\/www.franchise.com.hk\/en\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.franchise.com.hk\/en#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1\",\"width\":350,\"height\":76,\"caption\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\"},\"image\":{\"@id\":\"https:\/\/www.franchise.com.hk\/en#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869","og_locale":"en_US","og_type":"article","og_title":"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","og_description":"\u4e2d\u570b\u8607\u5dde\u548c\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e2024\u5e746\u670818\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u3001\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff1b\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u7684\u4e09\u9805\u7814\u7a76\u6700\u65b0\u6578\u64da\uff0c\u5df2\u57282024\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\u5e74\u6703\uff08EHA 2024\uff09\u4e0a\u4ee5\u58c1\u5831\u5f62\u5f0f\u516c\u4f48\u3002 \u5176\u4e2d\uff0c\u57282023\u5e74\u7f8e\u570b\u8840\u6db2\u5b78\u6703\u5e74\u6703\u516c\u4f48\u7684\u6578\u64da\u57fa\u790e\u4e0a\uff0c\u516c\u53f8\u66f4\u65b0\u4e86\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7814\u7a76\u7684\u4e2d\u4f4d1\u5e74\u96a8\u8a2a\u6578\u64da\u3002\u7d50\u679c\u986f\u793a\u5c0d\u65bc\u7d93\u904e\u591a\u500bTKI\u6cbb\u7642\uff08\u5305\u62ec\u5c0dponatinib\u6216\/\u548casciminib\u8010\u85e5\uff09\uff0c\u4f34\u6709\u6216\u4e0d\u4f34\u6709T315I\u7a81\u8b8a\uff0c\u8010\u7acb\u514b\u00ae\u90fd\u8868\u73fe\u51fa\u512a\u7570\u6301\u7e8c\u7684\u81e8\u5e8a\u7642\u6548\uff0c\u60a3\u8005\u9577\u671f\u85e5\u7269\u8010\u53d7\u6027\u826f\u597d\u3002 \u8a72\u9805\u81e8\u5e8a\u7814\u7a76\u7684\u4e3b\u8981\u7814\u7a76\u8005\u3001MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u767d\u8840\u75c5\u79d1\u7684Elia Jabbour\u535a\u58eb\u8868\u793a\uff1a\u300c\u7814\u7a76\u8868\u660e\uff0c\u8010\u7acb\u514b\u00ae\u5728\u91dd\u5c0d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684CML\u548cPh+ ALL\uff08\u5305\u62ec\u5c0dponatinib\u548casciminib\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff09\u7684\u60a3\u8005\u6642\uff0c\u5177\u6709\u986f\u8457\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002\u9019\u610f\u5473\u8457\u8010\u7acb\u514b\u00ae\u6709\u6f5b\u529b\u70ba\u9019\u4e00\u5177\u6709\u6311\u6230\u6027\u7684\u60a3\u8005\u7fa4\u9ad4\u63d0\u4f9b\u6709\u50f9\u503c\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u9700\u8981\u901a\u904e\u9577\u671f\u7814\u7a76\u9032\u4e00\u6b65\u9a57\u8b49\u5176\u81e8\u5e8a\u512a\u52e2\u3002\u300d \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4ee5\u5f80\u9032\u5c55\u548c\u672c\u6b21\u5728EHA\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u6700\u65b0\u6578\u64da\uff0c\u518d\u6b21\u8b49\u660e\u4e86\u8010\u7acb\u514b\u00ae\u5728ponatinib\u548casciminib\u8010\u85e5\u60a3\u8005\u4e2d\u7684\u5de8\u5927\u6f5b\u529b\u3002\u6211\u5011\u5c07\u52a0\u5feb\u9019\u4e00\u5168\u7403\u300eBest-in-class\u300f\u7522\u54c1\u7684\u81e8\u5e8a\u958b\u767c\uff0c\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d \u8010\u7acb\u514b\u00ae\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u5168\u7403\u5c64\u9762\u300cBest-in-class\u300d\u85e5\u7269\u3002\u4f5c\u70ba\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u8a72\u7522\u54c1\u76ee\u524d\u5df2\u6709\u5169\u9805\u9069\u61c9\u75c7\u7372\u6279\uff0c\u5206\u5225\u70ba\u6cbb\u7642\u4efb\u4f55TKI\u8010\u85e5\u3001\u4e26\u4f34\u6709T315I\u7a81\u8b8a\u7684CML\u6162\u6027\u671f\uff08-CP\uff09\u548c\u52a0\u901f\u671f\uff08-AP\uff09\u7684\u6210\u5e74\u60a3\u8005\uff1b\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8010\u7acb\u514b\u00ae\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u6709\u4e00\u9805\u6cbb\u7642\u521d\u6cbbPh+ ALL\u60a3\u8005\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\uff0c\u610f\u5473\u8457\u5176\u6709\u671b\u6210\u70ba\u570b\u5167\u9996\u500b\u7372\u6279\u7684\u7528\u65bcPh+ ALL\u4e00\u7dda\u6cbb\u7642\u7684TKI\u3002 EHA\u5e74\u6703\u4f5c\u70ba\u6b50\u6d32\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u6703\u8b70\uff0c\u6bcf\u5e74\u5438\u5f15\u4f86\u81ea\u5168\u7403100\u591a\u500b\u570b\u5bb6\u76841\u842c\u591a\u540d\u5c08\u696d\u4eba\u58eb\u8207\u6703\uff0c\u5206\u4eab\u5168\u7403\u6700\u524d\u6cbf\u7684\u7814\u7a76\u9032\u5c55\u548c\u7a81\u7834\u6027\u81e8\u5e8a\u6578\u64da\u3002\u4e9e\u76db\u91ab\u85e5\u9084\u5728\u672c\u5c46\u5927\u6703\u4e0a\u516c\u4f48\u4e86Bcl-2\u6291\u5236\u5291APG-2575\u3001EED\u6291\u5236\u5291APG-5918\u7684\u6700\u65b0\u7814\u7a76\u9032\u5c55\u3002 \u8010\u7acb\u514b\u00ae\u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff1a Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u5c0dPonatinib\u548cAsciminib\u7684\u8010\u85e5 \u6458\u8981\u7de8\u865f\uff1aP722 \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1aElias Jabbour\u535a\u58eb\uff0c\u5fb7\u5dde\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u4e00\u6b3e\u65b0\u578b\u5f37\u6548BCR::ABL1 TKI\uff0c\u76ee\u524d\u5df2\u6709\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u6578\u64da\u8b49\u5be6\u5176\u5728CML\u6216Ph+ ALL\u7684\u60a3\u8005\u4e2d\u5177\u6709\u5f37\u6548\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u9019\u662f\u4e00\u9805\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecPonatinib\u548cAsciminib\uff09\u7684CML\u6216Ph+ ALL\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a\u622a\u81f32024\u5e741\u67082\u65e5\uff0c\u672c\u7814\u7a76\u5171\u7d0d\u516580\u4f8b\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\u60a3\u8005\uff0c\u5305\u62ec62\u4f8bCML-CP\u548c18\u4f8b\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\uff08\u5305\u62ecCML-AP, CML-BP, \u548cPh+ ALL\uff09\u60a3\u8005\u3002\u60a3\u8005\u96a8\u6a5f\u5206\u914d\u81f330mg\u300140mg\u548c50 mg\u5291\u91cf\u7d44\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u63a1\u7528\u9694\u5929\u4e00\u6b21\uff08QOD\uff09\u53e3\u670d\u7d66\u85e5\u65b9\u6848\uff0c\u6bcf28\u5929\u70ba\u4e00\u500b\u7d66\u85e5\u9031\u671f\u3002 \u7642\u6548\u6578\u64da\uff1a 1)\u00a0 CML-CP\u60a3\u8005\uff1a 31\/51\uff0860.8%\uff09\u60a3\u8005\u7372\u5f97\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\uff0c25\/59\uff0842.4%\uff09\u60a3\u8005\u7372\u5f97\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u3002\u4e14\u53cd\u61c9\u7387\u8207\u662f\u5426\u4f34\u6709T315I\u7a81\u8b8a\u7121\u5dee\u7570\uff1b\u00a0 \u65e2\u5f80ponatinib\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u4e2d\uff0c\u517115\/26\uff0857.7%\uff09\u7372\u5f97CCyR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e5\u60a3\u800510\/19 [52.6%]\u4f8b\u548c\u4e0d\u8010\u53d7\u60a3\u80053\/4[75.0%]\u4f8b\uff09\uff1b\u517111\/30\uff0836.7%\uff09\u7372\u5f97MMR\uff08\u5305\u62ec\u65e2\u5f80Ponatinib\u8010\u85e59\/21[42.9%]\u548c\u4e0d\u8010\u53d71\/6[16.7%]\uff09\uff1b\u00a0 \u65e2\u5f80Asciminib\u6cbb\u7642\u8010\u85e5\u7684\u60a3\u8005\u4e2d\uff0c4\/8\uff0850.0%\uff09\u7372\u5f97CCyR, 4\/12\uff0833.3%\uff09\u7372\u5f97MMR\u3002 2)\u00a0 \u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\uff1a 3\/14\uff0821.4%\uff09\u60a3\u8005\u7372\u5f97CCyR\uff0c3\/17\uff0817.6%\uff09\u60a3\u8005\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a 72\u4f8b\uff0890.0%\uff09\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u7d93\u6b77\u4e86\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u5176\u4e2d\u5927\u90e8\u5206\u70ba\u8f15\u5ea6\u6216\u4e2d\u5ea6\uff1b \u8f03\u5e38\u898b\u7684\u22653\u7d1aTEAEs\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0817.5%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0812.5%\uff09\u548c\u8840\u808c\u9178\u78f7\u9178\u6fc0\u9176\u5347\u9ad8\uff0812.5%\uff09\uff1b\u767c\u751f\u5728\u22653\u4f8b\uff083.8%\uff09\u60a3\u8005\u4e2d\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\u5305\u62ec\u623f\u986b\u3001COVID-19\u611f\u67d3\u3001\u767c\u71b1\u6027\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u548c\u8178\u6897\u963b\uff1b\u7121\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAE\uff09\u5c0e\u81f4\u60a3\u8005\u6b7b\u4ea1\u3002\u5169\u4f8b\uff082.5%\uff09\u60a3\u8005\u767c\u751f1\u7d1a\u8207\u6cbb\u7642\u76f8\u95dc\u7684\u52d5\u8108\u8840\u7ba1\u9589\u585e\u4e8b\u4ef6\uff0c\u5206\u5225\u70ba\u5fc3\u7d5e\u75db\u548c\u5fc3\u529b\u8870\u7aed\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u63a5\u53d7\u91cd\u5ea6TKI\u6cbb\u7642\uff08\u5305\u62ecponatinib\u6216asciminib\u8010\u85e5\/\u4e0d\u8010\u53d7\uff09\u7684CML-CP\u548c\u9032\u5c55\u671fPh+\u767d\u8840\u75c5\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u6297\u816b\u7624\u4f5c\u7528\uff0c\u4e14\u8010\u53d7\u6027\u826f\u597d\u3002 Combination\u00a0of Third Generation\u00a0TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+\u00a0ALL Patients \u7b2c\u4e09\u4ee3TKI\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216Blinatumomab\u7528\u65bc\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684Ph+ ALL\u6210\u4eba\u60a3\u8005 \u6458\u8981\u7de8\u865f\uff1aP427 \u5c55\u793a\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76(Acute lymphoblastic leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1a\u9673\u4fca\u5091\uff0c\u5357\u65b9\u91ab\u79d1\u5927\u5b78\u5357\u65b9\u91ab\u9662 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1aTKI\u6539\u5584\u4e86Ph+ ALL\u60a3\u8005\u7684\u9577\u671f\u9810\u5f8c\uff0c\u4f46TKI\u8010\u85e5\u554f\u984c\u4ecd\u7136\u662f\u4e00\u500b\u6311\u6230\u3002\u65e2\u5f80\u5831\u544a\u986f\u793a\uff0c\u7b2c\u4e09\u4ee3TKI Ponatinib\u806f\u5408\u5316\u7642\u5728\u4e09\u500b\u6708\u5167\u7684\u5b8c\u5168\u5206\u5b50\u5b78\u7de9\u89e3\u7387\uff08CMR\uff09\u53ef\u905475%\u3002\u5728\u6700\u8fd1\u7684\u4e00\u9805\u7814\u7a76\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408PDT-ALL-2016\u65b9\u6848\u4e00\u7dda\u6cbb\u7642Ph+ ALL\u986f\u793a\u51fa\u4e86\u826f\u597d\u7684\u7d50\u679c\uff0c\u6cbb\u7642\u5f8c\u7b2c90\u5929\u7684CMR\u7387\u70ba84.6%\u3002\u6b64\u5916\uff0cTKI\u806f\u5408blinatumomab\uff08BITE\uff09\u7684\u7121\u5316\u7642\u65b9\u6848\u5df2\u986f\u793a\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\uff08TKI+\u5316\u7642\uff09\u53ca\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408blinatumomab\uff08TKI+BITE\uff09\u7528\u65bc\u4e00\u7dda\u6cbb\u7642 Ph+ ALL \u7684\u81e8\u5e8a\u7642\u6548\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a2022\u5e741\u6708\u81f32023\u5e7412\u6708\uff0c\u7814\u7a76\u5165\u7d44\u4e8631\u4f8b\u65b0\u78ba\u8a3a\u7684Ph+ ALL\u60a3\u8005\u3002\u9019\u4e9b\u60a3\u8005\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\uff0840mg\uff0c\u9694\u65e5\u4e00\u6b21\uff09\u806f\u5408\u5152\u7ae5\u555f\u767c\u5316\u7642\uff08n=19\uff1bPDT-ALL-2016\u65b9\u6848\uff09\u6216blinatumomab\uff08n=12\uff1b\u7d66\u85e52\u5468\uff0c 2\u5468\u7121\u6cbb\u7642\u9593\u6b47\u671f\uff09\u7684\u6cbb\u7642\u3002\u60a3\u8005\u4e2d\u4f4d\u5e74\u9f61\u70ba40\u6b72\uff0c15\u4f8b\uff0848.4%\uff09\u60a3\u8005\u5408\u4f751\u7a2e\u5408\u4f75\u75c7\uff0c8\u4f8b\uff0825.81%\uff09\u60a3\u8005\u67092\u7a2e\u4ee5\u4e0a\u5408\u4f75\u75c7\u3002 \u7642\u6548\u6578\u64da\uff1a\u4e2d\u4f4d\u96a8\u8a2a16\u500b\u6708\u5f8c\uff0c\u6240\u6709\u60a3\u8005\u5728\u63a5\u53d71\u500b\u6cbb\u7642\u9031\u671f\u5f8c\u5747\u7372\u5f97\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u3002\u7e3d\u968a\u5217\u4e2d\uff0c28\u4f8b\uff0890.3%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u5176\u4e2d\uff0cTKI+\u5316\u7642\u968a\u5217\u548cTKI+BITE\u968a\u5217\u5206\u5225\u670916\u4f8b\uff0884.2%\uff09\u548c12\u4f8b\uff08100.0%\uff09\u60a3\u8005\u5728\u4e09\u500b\u6708\u5167\u9054\u5230CMR\u3002\u7e3d\u968a\u5217\u76841\u5e74\u7e3d\u751f\u5b58\uff08OS\uff09\u7387\u70ba93.1%\uff0c\u7121\u4e8b\u4ef6\u751f\u5b58\uff08EFS\uff09\u7387\u70ba78.4%\u3002TKI+\u5316\u7642\u968a\u5217\u76841\u5e74OS\u7387\u70ba96.2%\uff0cEFS\u7387\u70ba71.5%\u3002TKI+BITE\u968a\u5217\u76841\u5e74OS\u7387\u70ba 100.0%\uff0cEFS\u7387\u70ba90.0%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u572810\u4f8b\uff0832.3%\uff09\u60a3\u8005\u4e2d\u89c0\u5bdf\u5230\u4e0d\u826f\u4e8b\u4ef6\uff0c3\u4f8b\uff089.6%\uff09\u60a3\u8005\u5728\u6cbb\u7642\u671f\u9593\u767c\u751f\u611f\u67d3\u6027\u4f11\u514b\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u51fa\u73fe\u8f15\u5ea6\u80f0\u817a\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f\u8036\u6c0f\u80ba\u5b62\u5b50\u83cc\u80ba\u708e\uff1b2\u4f8b\uff086.4%\uff09\u60a3\u8005\u767c\u751f2\u7d1a\u7d30\u80de\u56e0\u5b50\u91cb\u653e\u7d9c\u5408\u5f81\uff08CRS\uff09\uff1b1\u4f8b\uff083.2%\uff09\u60a3\u8005\u767c\u751f\u80ba\u6813\u585e\u3002 \u7d50\u8ad6\uff1a\u9019\u9805\u7814\u7a76\u5c0d\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6216blinatumomab\u6cbb\u7642\u6210\u4ebaPh+ ALL\u60a3\u8005\u9032\u884c\u4e86\u8a55\u4f30\u3002\u5728\u5165\u7d44\u768431\u4f8b\u60a3\u8005\u4e2d\uff0c\u89c0\u5bdf\u5230\u4e86\u986f\u8457\u76841\u5e74\u751f\u5b58\u7387\u548cCMR \u7387\uff0c\u9019\u70ba\u63d0\u9ad8\u9577\u671f\u751f\u5b58\u7387\u5e36\u4f86\u4e86\u5e0c\u671b\u3002TKI+\u5316\u7642\u548cTKI+BITE\u968a\u5217\u90fd\u986f\u793a\u4e86\u826f\u597d\u7684\u81e8\u5e8a\u7d50\u679c\uff0c\u4e14TKI+BITE\u968a\u5217\u7684\u751f\u5b58\u6f5b\u529b\u512a\u65bcTKI+\u5316\u7642\u968a\u5217\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u5118\u7ba174.19%\u7684\u60a3\u8005\u6709\u81f3\u5c11\u4e00\u7a2e\u5408\u4f75\u75c7\uff0c\u4e2d\u4f4d\u5e74\u9f61\u905440\u6b72\uff0c\u5b89\u5168\u6027\u4ecd\u53ef\u63a5\u53d7\u3002 Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy \u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u6210\u5e74\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40 \u6458\u8981\u7de8\u865f\uff1aP1862 \u5c55\u793a\u985e\u578b\uff1a\u96fb\u5b50\u58c1\u5831\u5c55\u793a \u5206\u6703\u5834\u6a19\u984c\uff1a\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5 \u2013 \u81e8\u5e8a\u7814\u7a76 (Chronic myeloid leukemia \u2013 Clinical) \u65e5\u671f\u53ca\u6642\u9593\uff1a2024\u5e746\u670814\u65e5\uff0c\u661f\u671f\u4e94 18:00 \u2013 19:00 (\u6b50\u6d32\u4e2d\u90e8\u6642\u9593) \/ 2024\u5e746\u670815\u65e5\uff0c\u661f\u671f\u516d 00:00 \u2013 01:00 (\u5317\u4eac\u6642\u9593) \u5831\u544a\u4eba\uff1a\u65bc\u9732\uff0c\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662 \u6838\u5fc3\u8981\u9ede\uff1a \u7814\u7a76\u80cc\u666f\uff1a\u7b2c\u4e09\u4ee3TKI\u6539\u5584\u4e86TKI\u8010\u85e5\u7684CML\u60a3\u8005\u7684\u9810\u5f8c\u3002\u7136\u800c\uff0c\u95dc\u65bc\u63a5\u53d7\u5982\u5967\u96f7\u5df4\u66ff\u5c3c\u7b49\u7b2c\u4e09\u4ee3TKI\u7684\u6210\u5e74\u60a3\u8005\u7684\u60a3\u8005\u5831\u544a\u7d50\u5c40\u6578\u64da\u5f88\u5c11\u3002 \u7814\u7a76\u4ecb\u7d39\uff1a\u8a72\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5CML\u60a3\u8005\u7684\u5065\u5eb7\u76f8\u95dc\u751f\u6d3b\u8cea\u91cf\uff08HRQoL\uff09\u3001\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\uff0c\u4e26\u78ba\u5b9a\u8207\u4e4b\u76f8\u95dc\u7684\u8b8a\u91cf\u3002 \u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a \u8a72\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\u4e2d\uff0c\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684TKI\u8010\u85e5\u7684\u60a3\u8005\u5728\u57fa\u7dda\u4ee5\u53ca\u6cbb\u7642\u671f\u9593\u5b9a\u671f\u5b8c\u6210\u6b50\u6d32\u764c\u75c7\u7814\u7a76\u8207\u6cbb\u7642\u7d44\u7e54\uff08EORTC\uff09\u751f\u547d\u8cea\u91cf\u8a55\u4f30\u554f\u5377\uff08QLQ-C30\uff09\u3001\u7126\u616e\u81ea\u8a55\u91cf\u8868\uff08SAS\uff09\u548c\u6291\u9b31\u81ea\u8a55\u91cf\u8868\uff08SDS\uff09\u3002\u7814\u7a76\u901a\u904e\u57fa\u65bc\u7368\u7acb\u5de5\u4f5c\u76f8\u95dc\u77e9\u9663\u7684\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u7dda\u6027\u6a21\u578b\uff0c\u4f30\u8a08\u60a3\u8005\u5831\u544a\u7d50\u5c40\u96a8\u6642\u9593\u8b8a\u5316\u8da8\u52e2\uff0c\u4e26\u4f7f\u7528\u5ee3\u7fa9\u4f30\u8a08\u65b9\u7a0b\u6a21\u578b\u8a55\u4f30\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u548c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684\u6cbb\u7642\u53cd\u61c9\u5c0dHRQoL\u3001SAS\u548cSDS\u7684\u5f71\u97ff\u3002 \u672c\u7814\u7a76\u5171\u7d0d\u5165159\u4f8b\u8655\u65bcCP\u6216AP\u7684CML\u60a3\u8005\u3002\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f61\u70ba 42\uff0820-74\uff09\u6b72\u3002104\u4f8b\uff0865%\uff09\u60a3\u8005\u70ba\u7537\u6027\u3002\u5f9e\u78ba\u8a3aCML\u5230\u958b\u59cb\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7684\u6642\u9593\u9593\u9694\u70ba5\uff080.3-23\uff09\u5e74\u300277\u4f8b\uff0848%\uff09\u60a3\u8005\u5728\u78ba\u8a3aCML\u5f8c\u76845\u5e74\u5167\u63a5\u53d7\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u3002\u6240\u6709\u60a3\u8005\u90fd\u5b8c\u6210\u4e86QLQ-C30\u554f\u5377\uff0c115\u4f8b\u60a3\u8005\u5b8c\u6210\u4e86SAS\u548cSDS\u554f\u5377\u3002 \u554f\u5377\u6578\u64da\uff1a \u6839\u64daEORTC QLQ-C30\u554f\u5377\u8a55\u4f30\uff0c\u57fa\u7dda\u6642\u6700\u56b4\u91cd\u76843\u7a2e\u75c7\u72c0\u8ca0\u64d4\u70ba\u7d93\u6fdf\u56f0\u96e3\u3001\u75b2\u52de\u548c\u5931\u7720\u3002\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\uff0c\u5305\u62ec\u6574\u9ad4\u5065\u5eb7\u3001\u8eab\u9ad4\u529f\u80fd\u3001\u60c5\u611f\u529f\u80fd\u3001\u75b2\u52de\u3001\u75bc\u75db\u3001\u547c\u5438\u56f0\u96e3\u3001\u8179\u7009\u548c\u7d93\u6fdf\u56f0\u96e3\u5728\u5167\u76848\u500b\u91cf\u8868\u9805\u76ee\u7372\u5f97\u986f\u8457\u6539\u5584\u3002\u6c92\u6709\u91cf\u8868\u9805\u76ee\u51fa\u73fe\u986f\u8457\u60e1\u5316\u3002\u5728\u591a\u8b8a\u91cf\u5206\u6790\u4e2d\uff0c\u5e74\u9f61&lt;40\u6b72\u8207\u66f4\u597d\u7684\u793e\u6703\u529f\u80fd\u6539\u5584\u76f8\u95dc\uff08p=0.021\uff09\uff1bCP\u60a3\u8005\uff08\u8207AP\u76f8\u6bd4\uff09\u547c\u5438\u56f0\u96e3\uff08p=0.028\uff09\u548c\u8179\u7009\uff08p=0.042\uff09\u5f97\u5230\u66f4\u597d\u7684\u6539\u5584\uff1b\u9054\u5230MMR\u5f8c\uff0c\u6574\u9ad4\u5065\u5eb7\uff08p=0.005\uff09\u3001\u5641\u5fc3\u5614\u5410\uff08p=0.009\uff09\u548c\u8179\u7009\uff08p=0.001\uff09\u90fd\u7372\u5f97\u66f4\u597d\u7684\u6539\u5584\u3002 \u57fa\u7dda\u6642\uff0c\u6839\u64daSAS\u8a55\u5206\uff0c\u670996\u4f8b\uff0884%\uff09\u60a3\u8005\u6b63\u5e38\uff0c19\u4f8b\uff0816%\uff09\u60a3\u8005\u6709\u8f15\u5ea6\u6216\u4e2d\u5ea6\u7126\u616e\u75c7\u72c0\u3002\u6839\u64daSDS\u8a55\u5206\uff0c64\u4f8b\uff0856%\uff09\u60a3\u8005\u6b63\u5e38\uff1b37\u4f8b\uff0832%\uff09\u6709\u8f15\u5ea6\u6291\u9b31\u75c7\u72c0\uff0c14\u4f8b\uff0812%\uff09\u6709\u4e2d\u5ea6\u6216\u91cd\u5ea6\u6291\u9b31\u75c7\u72c0\u3002SAS\u8a55\u5206\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u96a8\u6642\u9593\u63a8\u9032\u986f\u8457\u964d\u4f4e\uff08p&lt;0.001\uff09\uff0c\u800cSDS\u8a55\u5206\u6c92\u6709\u986f\u8457\u8b8a\u5316\u3002\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642 \u7684\u7b2c36\u500b\u6708\uff0c\u5206\u5225\u670978\u4f8b\uff0895%\uff09\u548c48\u4f8b\uff0859%\uff09\u60a3\u8005\u6839\u64daSAS\u548cSDS\u554f\u5377\u8a55\u4f30\u7d50\u679c\u88ab\u8a8d\u5b9a\u70ba\u6c92\u6709\u7126\u616e\u548c\u6291\u9b31\u75c7\u72c0\u3002\u6c92\u6709\u767c\u73fe\u4efb\u4f55\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u5f71\u97ffSAS\u8a55\u5206\u8b8a\u5316\u7684\u8b8a\u91cf\u3002 \u7d50\u8ad6\uff1aTKI\u8010\u85e5CML\u60a3\u8005\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u671f\u9593\u7684HRQoL\u548c\u7126\u616e\u75c7\u72c0\u96a8\u6642\u9593\u7684\u5ef6\u9577\u6709\u986f\u8457\u6539\u5584\u3002\u5e74\u9f61\u8f03\u5c0f\uff0c\u8655\u65bcCP\u671f\uff0c\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u4e2d\u9054\u5230MMR\u7684\u60a3\u8005\u7684HRQoL\u6539\u5584\u60c5\u6cc1\u66f4\u597d\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u570b\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u5728\u816b\u7624\u3001\u4e59\u809d\u53ca\u8207\u8870\u8001\u76f8\u95dc\u7684\u75be\u75c5\u7b49\u6cbb\u7642\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9e\u76db\u91ab\u85e5\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\u3002 \u4e9e\u76db\u91ab\u85e5\u64c1\u6709\u81ea\u4e3b\u69cb\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u85e5\u7269\u8a2d\u8a08\u5e73\u53f0\uff0c\u8655\u65bc\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u85e5\u7814\u767c\u7684\u5168\u7403\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u64c1\u67099\u500b\u5df2\u9032\u5165\u81e8\u5e8a\u958b\u767c\u968e\u6bb5\u76841\u985e\u5c0f\u5206\u5b50\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP\u6216MDM2-p53\u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\uff0c\u70ba\u5168\u7403\u552f\u4e00\u5728\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u9818\u57df\u5747\u6709\u81e8\u5e8a\u958b\u767c\u54c1\u7a2e\u7684\u5275\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u570b\u3001\u7f8e\u570b\u3001\u6fb3\u5927\u5229\u4e9e\u53ca\u6b50\u6d32\u958b\u5c5540\u591a\u9805\u81e8\u5e8a\u8a66\u9a57\uff0c\u5176\u4e2d5\u9805\u70ba\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\u3002 \u7528\u65bc\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u7a2e\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u66fe\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u65b0\u85e5\u5be9\u8a55\u4e2d\u5fc3\uff08CDE\uff09\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u548c\u7a81\u7834\u6027\u6cbb\u7642\u54c1\u7a2e\uff0c\u4e26\u5df2\u5728\u4e2d\u570b\u7372\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u500b\u4e0a\u5e02\u54c1\u7a2e\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u00ae\u5df2\u88ab\u6210\u529f\u7d0d\u5165\u300a\u570b\u5bb6\u57fa\u672c\u91ab\u7642\u4fdd\u96aa\u3001\u5de5\u50b7\u4fdd\u96aa\u548c\u751f\u80b2\u4fdd\u96aa\u85e5\u54c1\u76ee\u9304(2022\u5e74)\u300b\u3002\u8a72\u54c1\u7a2e\u9084\u7372\u5f97\u4e86\u7f8e\u570bFDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u3001\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3001\u4ee5\u53ca\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u500b\u5728\u7814\u65b0\u85e5\u7372\u5f9716\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u516c\u53f8\u5148\u5f8c\u627f\u64d4\u591a\u9805\u570b\u5bb6\u79d1\u6280\u91cd\u5927\u5c08\u9805\uff0c\u5176\u4e2d\u300c\u91cd\u5927\u65b0\u85e5\u5275\u88fd\u300d\u5c08\u98055\u9805\uff0c\u5305\u62ec1\u9805\u300c\u4f01\u696d\u5275\u65b0\u85e5\u7269\u5b75\u5316\u57fa\u5730\u300d\u53ca4\u9805\u300c\u5275\u65b0\u85e5\u7269\u7814\u767c\u300d\uff0c\u53e6\u5916\u627f\u64d4\u300c\u91cd\u5927\u50b3\u67d3\u75c5\u9632\u6cbb\u300d\u5c08\u98051\u9805\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207UNITY\u3001MD Anderson\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u7b49\u9818\u5148\u7684\u751f\u7269\u6280\u8853\u53ca\u91ab\u85e5\u516c\u53f8\u3001\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u8c50\u5bcc\u7684\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u7d93\u9a57\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u540c\u6642\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6a19\u6e96\u6253\u9020\u5f8c\u671f\u7684\u5546\u696d\u5316\u751f\u7522\u53ca\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u8207\u672c\u6587\u4f5c\u51fa\u8a72\u9673\u8ff0\u7576\u65e5\u7684\u4e8b\u4ef6\u6216\u8cc7\u6599\u6709\u95dc\u3002\u9664\u6cd5\u5f8b\u898f\u5b9a\u5916\uff0c\u65bc\u4f5c\u51fa\u524d\u77bb\u6027\u9673\u8ff0\u7576\u65e5\u4e4b\u5f8c\uff0c\u7121\u8ad6\u662f\u5426\u51fa\u73fe\u65b0\u8cc7\u6599\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u6211\u5011\u4e26\u7121\u8cac\u4efb\u66f4\u65b0\u6216\u516c\u958b\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u9810\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8acb\u7d30\u95b1\u672c\u6587\uff0c\u4e26\u7406\u89e3\u6211\u5011\u7684\u5be6\u969b\u672a\u4f86\u696d\u7e3e\u6216\u8868\u73fe\u53ef\u80fd\u8207\u9810\u671f\u6709\u91cd\u5927\u5dee\u7570\u3002\u672c\u6587\u5167\u6240\u6709\u9673\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u767c\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u4f86\u767c\u5c55\u800c\u51fa\u73fe\u8b8a\u52d5\u3002","og_url":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869","og_site_name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","article_published_time":"2024-06-17T20:15:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869#article","isPartOf":{"@id":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869"},"author":{"name":"","@id":""},"headline":"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277","datePublished":"2024-06-17T20:15:00+00:00","dateModified":"2024-06-17T20:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869"},"wordCount":305,"publisher":{"@id":"https:\/\/www.franchise.com.hk\/en#organization"},"articleSection":["\u672a\u5206\u985e"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869","url":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869","name":"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277 - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","isPartOf":{"@id":"https:\/\/www.franchise.com.hk\/en#website"},"datePublished":"2024-06-17T20:15:00+00:00","dateModified":"2024-06-17T20:15:00+00:00","breadcrumb":{"@id":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.franchise.com.hk\/en\/%e3%80%90%e7%9b%b4%e6%93%8aeha-2024%e3%80%91%e8%80%90%e7%ab%8b%e5%85%8b%e4%b8%89%e9%a0%85%e7%a0%94%e7%a9%b6%e9%80%b2%e5%b1%95%e5%85%a5%e9%81%b8%ef%bc%8c%e6%b2%bb%e7%99%82cml%e5%92%8cph-all\/19869#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/www.franchise.com.hk\/en"},{"@type":"ListItem","position":2,"name":"\u3010\u76f4\u64caEHA 2024\u3011\u8010\u7acb\u514b\u00ae\u4e09\u9805\u7814\u7a76\u9032\u5c55\u5165\u9078\uff0c\u6cbb\u7642CML\u548cPh+ ALL\u7684\u6d77\u5916\u6578\u64da\u9a5a\u8277"}]},{"@type":"WebSite","@id":"https:\/\/www.franchise.com.hk\/en#website","url":"https:\/\/www.franchise.com.hk\/en","name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","description":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df | Franchise HK","publisher":{"@id":"https:\/\/www.franchise.com.hk\/en#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.franchise.com.hk\/en?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.franchise.com.hk\/en#organization","name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","url":"https:\/\/www.franchise.com.hk\/en","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.franchise.com.hk\/en#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1","width":350,"height":76,"caption":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df"},"image":{"@id":"https:\/\/www.franchise.com.hk\/en#\/schema\/logo\/image\/"}}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2024\/06\/Ascentage_Pharma_Logo-RMSQl6.jpeg?fit=597%2C115&ssl=1","_links":{"self":[{"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/posts\/19869"}],"collection":[{"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/comments?post=19869"}],"version-history":[{"count":0,"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/posts\/19869\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/media\/19870"}],"wp:attachment":[{"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/media?parent=19869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/categories?post=19869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.franchise.com.hk\/en\/wp-json\/wp\/v2\/tags?post=19869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}